WO2012137970A1 - 改変ラミニンおよびその利用 - Google Patents
改変ラミニンおよびその利用 Download PDFInfo
- Publication number
- WO2012137970A1 WO2012137970A1 PCT/JP2012/059720 JP2012059720W WO2012137970A1 WO 2012137970 A1 WO2012137970 A1 WO 2012137970A1 JP 2012059720 W JP2012059720 W JP 2012059720W WO 2012137970 A1 WO2012137970 A1 WO 2012137970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- laminin
- cells
- cell
- human
- chain
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 335
- 239000012634 fragment Substances 0.000 claims abstract description 139
- 238000000034 method Methods 0.000 claims abstract description 80
- 238000012258 culturing Methods 0.000 claims abstract description 38
- 230000010261 cell growth Effects 0.000 claims abstract description 22
- 230000001105 regulatory effect Effects 0.000 claims abstract description 9
- 102000007547 Laminin Human genes 0.000 claims description 326
- 108010085895 Laminin Proteins 0.000 claims description 326
- 230000027455 binding Effects 0.000 claims description 57
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 41
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 41
- 239000000758 substrate Substances 0.000 claims description 41
- 239000003102 growth factor Substances 0.000 claims description 40
- 230000021164 cell adhesion Effects 0.000 claims description 32
- 108010044426 integrins Proteins 0.000 claims description 27
- 102000006495 integrins Human genes 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 25
- 230000008672 reprogramming Effects 0.000 claims description 23
- 238000012136 culture method Methods 0.000 claims description 17
- 210000004962 mammalian cell Anatomy 0.000 claims description 13
- 108010067306 Fibronectins Proteins 0.000 claims description 12
- 102000016359 Fibronectins Human genes 0.000 claims description 12
- 210000001082 somatic cell Anatomy 0.000 claims description 12
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 claims description 10
- 108010049224 perlecan Proteins 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 108010086803 nephronectin Proteins 0.000 claims description 7
- 102000006776 nephronectin Human genes 0.000 claims description 7
- 101150079978 AGRN gene Proteins 0.000 claims description 6
- 102100040026 Agrin Human genes 0.000 claims description 6
- 108700019743 Agrin Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 108010031318 Vitronectin Proteins 0.000 claims description 6
- 102100035140 Vitronectin Human genes 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 210000001988 somatic stem cell Anatomy 0.000 claims description 6
- 102100032029 Epidermal growth factor-like protein 6 Human genes 0.000 claims description 5
- 101000921196 Homo sapiens Epidermal growth factor-like protein 6 Proteins 0.000 claims description 5
- 101000662534 Homo sapiens Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 Proteins 0.000 claims description 5
- 108010081689 Osteopontin Proteins 0.000 claims description 5
- 102000004264 Osteopontin Human genes 0.000 claims description 5
- 102000016611 Proteoglycans Human genes 0.000 claims description 5
- 108010067787 Proteoglycans Proteins 0.000 claims description 5
- 102100037409 Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 Human genes 0.000 claims description 5
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 5
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims description 5
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000007623 Dystroglycans Human genes 0.000 claims description 4
- 108010071885 Dystroglycans Proteins 0.000 claims description 4
- 102000010956 Glypican Human genes 0.000 claims description 4
- 108050001154 Glypican Proteins 0.000 claims description 4
- 108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 claims description 4
- 102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 claims description 4
- 108010008125 Tenascin Proteins 0.000 claims description 4
- 102000007000 Tenascin Human genes 0.000 claims description 4
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 4
- 102000002706 Discoidin Domain Receptors Human genes 0.000 claims description 3
- 108010043648 Discoidin Domain Receptors Proteins 0.000 claims description 3
- 241000131390 Glis Species 0.000 claims description 3
- 102000019361 Syndecan Human genes 0.000 claims description 3
- 108050006774 Syndecan Proteins 0.000 claims description 3
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 abstract description 85
- 239000003814 drug Substances 0.000 abstract description 9
- 230000001172 regenerating effect Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 7
- 239000013638 trimer Substances 0.000 abstract description 6
- 239000013604 expression vector Substances 0.000 description 50
- 239000000243 solution Substances 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 38
- 101150086694 SLC22A3 gene Proteins 0.000 description 35
- 108010082117 matrigel Proteins 0.000 description 32
- 239000002609 medium Substances 0.000 description 28
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 27
- 239000011248 coating agent Substances 0.000 description 27
- 238000000576 coating method Methods 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 26
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 23
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 210000002744 extracellular matrix Anatomy 0.000 description 23
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 22
- 239000001963 growth medium Substances 0.000 description 21
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 20
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 20
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 102100027450 Laminin subunit alpha-5 Human genes 0.000 description 18
- 108010088360 laminin alpha5 Proteins 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 238000004113 cell culture Methods 0.000 description 16
- 210000001778 pluripotent stem cell Anatomy 0.000 description 16
- 230000004927 fusion Effects 0.000 description 15
- 108010042502 laminin A Proteins 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 108010038862 laminin 10 Proteins 0.000 description 13
- 238000012423 maintenance Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000003321 amplification Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 101150111214 lin-28 gene Proteins 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 8
- -1 TERT Proteins 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 239000003656 tris buffered saline Substances 0.000 description 8
- 102000000905 Cadherin Human genes 0.000 description 7
- 108050007957 Cadherin Proteins 0.000 description 7
- 101001008568 Homo sapiens Laminin subunit beta-1 Proteins 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 102000051283 human LAMB1 Human genes 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 5
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 101150099612 Esrrb gene Proteins 0.000 description 4
- 102000002090 Fibronectin type III Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000004266 Collagen Type IV Human genes 0.000 description 3
- 108010042086 Collagen Type IV Proteins 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 210000004900 c-terminal fragment Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 108010007093 dispase Proteins 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 2
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000047200 Collagen Type XVIII Human genes 0.000 description 2
- 108010001463 Collagen Type XVIII Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150033269 ESRRG gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000016970 Follistatin Human genes 0.000 description 2
- 108010014612 Follistatin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 2
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 2
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 2
- 108050000637 N-cadherin Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101150001847 Sox15 gene Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000004956 cell adhesive effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108050007238 Glypican-1 Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101100510266 Homo sapiens KLF4 gene Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101100137155 Homo sapiens POU5F1 gene Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101100094846 Homo sapiens SLC22A3 gene Proteins 0.000 description 1
- 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100404103 Mus musculus Nanog gene Proteins 0.000 description 1
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 235000003846 Ricinus Nutrition 0.000 description 1
- 241000322381 Ricinus <louse> Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000003705 Syndecan-1 Human genes 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 108010039433 dolichos biflorus agglutinin Proteins 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000051629 human Lin28A Human genes 0.000 description 1
- 102000047444 human SOX2 Human genes 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 108010090909 laminin gamma 1 Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102220005293 rs35960772 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
Definitions
- the present invention relates to a modified human laminin and use thereof. Specifically, the present invention relates to a modified human laminin in which a cell growth regulatory molecule is bound to laminin or a fragment thereof, a cell culture method using the modified human laminin, a method for establishing iPS cells, and the The present invention relates to a culture substrate coated with modified human laminin.
- Stem cells especially pluripotent stem cells such as ES cells and iPS cells, are attracting attention worldwide for their application in regenerative medicine.
- the cells are usually used as feeder cells as fibroblasts derived from mouse embryos that have been treated with radiation or antibiotics to stop cell division ( Incubated in the presence of MEF).
- STO cells are usually used as MEFs, but SNL cells (McMahon, A. P. & Bradley, A. Cell 62, 1073-1085 (1990)) are often used to induce iPS cells. ing.
- SNL cells McMahon, A. P. & Bradley, A. Cell 62, 1073-1085 (1990)
- the use of these feeder cells is a major limitation.
- Matrigel is known to contain abundant basement membrane components such as laminin and type IV collagen, its composition has not been completely elucidated, and since it is derived from a mouse, it is human in regenerative medicine. It is not suitable for stem cell culture.
- Laminin is a major cell adhesion molecule of the basement membrane, a heterotrimer composed of three subunit chains of ⁇ chain, ⁇ chain and ⁇ chain, and is a huge glycoprotein with a molecular weight of 800,000 Da. Three subunit chains associate on the C-terminal side to form a coiled-coil structure and form a heterotrimeric molecule stabilized by disulfide bonds.
- the present inventors have reported that a recombinant protein of human laminin (particularly laminin 332 consisting of ⁇ 3 ⁇ 3 ⁇ 2 and laminin 511 consisting of ⁇ 5 ⁇ 1 ⁇ 1) is effective in maintaining the pluripotency of human ES cells (non-patent literature). 1).
- adhesion receptors other than laminin receptors are also expressed on the surface of human stem cells. Ineffective use of receptors. Therefore, development of a new human-derived extracellular matrix having adhesion activity closer to that of nature and capable of culturing human stem cells under feeder-free conditions is eagerly desired.
- the present invention relates to a culture substrate capable of maintaining and culturing stem cells while maintaining pluripotency in a feeder-free culture environment, a cell culture method and iPS cell establishment method using the culture substrate, and a coating on the extracellular matrix It is an object of the present invention to provide a cultured substrate.
- the present invention includes the following inventions in order to solve the above problems.
- Cell growth control at least one position of laminin or ⁇ -chain N-terminus, ⁇ -chain C-terminus, ⁇ -chain N-terminus and ⁇ -chain N-terminus of laminin fragment forming heterotrimer A modified laminin characterized in that the molecules are bound.
- the modified laminin according to [1], wherein the cell growth control molecule is a growth factor binding molecule.
- the laminin is composed of one ⁇ chain selected from ⁇ 1 to ⁇ 5, one ⁇ chain selected from ⁇ 1 to ⁇ 3, and one ⁇ chain selected from ⁇ 1 to ⁇ 3.
- A a fragment containing fibronectin or its cell adhesion active site
- b a fragment containing collagen or its cell adhesion active site
- c a fragment containing vitronectin or its cell adhesion active site
- d nephronectin or its cell adhesion active site
- E Fragment containing osteopontin or its cell adhesion active site
- f Fragment containing MAEG or its cell adhesion active site
- g Tenascin or fragment containing its cell adhesion active site
- h SVEP1 or its cell Fragment containing an adhesion active site
- i TGF- ⁇ 1 late associated peptide or fragment containing its cell adhesion active site
- j TGF- ⁇ 3 late associated p eptide or fragment containing the cell adhesion active site
- k globular domain 4 and / or 5 of laminin ⁇ chain Spherical domain 4 and / or 5 of laminin ⁇ chain
- [12] A method for culturing mammalian cells, comprising culturing in the presence of the modified human laminin according to any one of [1] to [11].
- the culture method according to [12], wherein the mammalian cells are ES cells, iPS cells, or somatic stem cells.
- [16] The culture substrate according to [15], wherein the modified human laminin is coated at a concentration of 0.03 to 25 ⁇ g / cm 2 .
- a method for establishing an iPS cell comprising a step of bringing a nuclear reprogramming substance into contact with a somatic cell in the presence of the modified laminin according to any one of [1] to [11].
- the nuclear reprogramming substance includes one or more kinds of substances selected from the group consisting of Oct family, Sox family, Klf family, Lin family and Glis family and nucleic acids encoding them. The method for establishing iPS cells according to [17].
- modified human laminin as an extracellular matrix capable of maintaining and culturing stem cells while maintaining pluripotency in a feeder-free culture environment, a cell culture method and iPS cell establishment method using the modified human laminin, and A culture substrate coated with modified human laminin can be provided.
- human-derived modified human laminin to establish iPS cells in a xeno-free medium or culturing human stem cells, highly safe human stem cells that can be applied to regenerative medicine can be provided.
- FIG. 3 is a diagram showing the results of SDS-PAGE analysis of modified human laminin (hereinafter referred to as “Plus # 2 laminin E8”). It is a figure which shows the result of having compared the density
- Modified human laminin (hereinafter referred to as “Plus # 3 laminin E8”) or E8 fragment of human laminin ⁇ 5 ⁇ 1 ⁇ 1, in which E8 fragment of Plus # 1 laminin E8, Plus # 2 laminin E8, human laminin ⁇ 5 ⁇ 1 ⁇ 1 and human perlecan domains I to III are fused, Or it is a figure which shows the result of having cultured the human iPS cell using the culture base material which coated Matrigel for 7 days, and confirming engraftment.
- Human iPS cells are subcultured for 10 passages using a culture substrate coated with Plus # 1 laminin E8 or Plus # 2 laminin E8, and immunized with undifferentiated markers Oct3 / 4, SSEA-4 and TRA-1-60 It is a figure which shows the dyeing
- FIG. 2 shows the structure of an episomal plasmid vector, where (I) is pCEB-hSK-O and (II) is pCEB-hUL-G.
- the present invention relates to cell growth in at least one of the N-terminus of the ⁇ chain, the C-terminus of the ⁇ -chain, the N-terminus of the ⁇ -chain and the N-terminus of the ⁇ -chain of laminin or a laminin fragment forming a heterotrimer.
- a modified laminin characterized in that a regulatory molecule is attached.
- Laminin is a heterotrimeric molecule composed of three subunit chains, an ⁇ chain, a ⁇ chain, and a ⁇ chain.
- the laminin constituting the modified laminin of the present invention may be any isoform. That is, the laminin constituting the modified laminin of the present invention has one ⁇ chain selected from ⁇ 1 to ⁇ 5, one ⁇ chain selected from ⁇ 1 to ⁇ 3, and one ⁇ selected from ⁇ 1 to ⁇ 3. What consists of a chain
- strand should just be sufficient. Specifically, twelve types described in Table 1 and all other isoforms can be suitably used. Laminin ⁇ 3 ⁇ 3 ⁇ 2 and laminin ⁇ 5 ⁇ 1 ⁇ 1 are preferable.
- laminin The origin of laminin is not particularly limited, and laminin derived from various organisms can be used.
- Laminin derived from a mammal is preferable. Examples of mammals include, but are not limited to, humans, mice, rats, cows, pigs and the like. Among these, it is particularly preferable to use human-derived laminin.
- human-derived laminin When culturing human stem cells to obtain materials for human regenerative medicine, it is preferable to use human-derived laminin because a culture environment that satisfies the xeno-free condition of excluding heterogeneous components from the culture system is required. .
- the laminin constituting the modified laminin of the present invention may be full length or a fragment thereof. That is, it may be a full-length laminin consisting of a full-length ⁇ chain, a full-length ⁇ chain and a full-length ⁇ chain, or a laminin fragment where at least one of the ⁇ chain, ⁇ chain and ⁇ chain is a fragment shorter than the full length. .
- the laminin fragment is required to form a heterotrimer.
- the laminin fragment preferably has integrin binding activity. It can be confirmed that the laminin fragment forms a heterotrimer by subjecting the laminin fragment to SDS-PAGE and detecting the number of bands (see Example 1). Whether the laminin fragment has integrin binding activity can be confirmed by ELISA or the like (see Example 4).
- the laminin fragment constituting the modified laminin of the present invention is not particularly limited as long as it forms a heterotrimer composed of an ⁇ chain, a ⁇ chain, and a ⁇ chain. From the viewpoint of strength of integrin binding activity and expression efficiency as a recombinant protein (that can be produced in a high yield as a recombinant protein compared to full-length laminin), an E8 fragment of laminin is preferred.
- the E8 fragment of laminin was identified as a fragment having strong cell adhesion activity among fragments obtained by digesting mouse laminin ⁇ 1 ⁇ 1 ⁇ 1 (hereinafter referred to as “mouse laminin 111”) with elastase (Edgar D ., Timpl R., Thoenen H.The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival. EMBO J., 3: 1463-1468, 1984., Goodman SL., DeutzvonR. der Mark K.Two distinct cell-binding domains in laminin can independently promote nonneuronal cell adhesion and spreading. J. Cell Biol., 105: 589-598, 1987.).
- laminin other than mouse laminin 111 is also digested with elastase, the presence of a fragment corresponding to the E8 fragment of mouse laminin 111 is presumed, but laminin other than mouse laminin 111 is digested with elastase to isolate and identify the E8 fragment. None has been reported. Therefore, the laminin E8 used in the present invention does not need to be a laminin elastase digestion product, has the same cell adhesion activity as the E8 of mouse laminin 111, has the same structure, and the same level. Any fragment of laminin having a molecular weight may be used.
- Laminin may be a natural type or a modified type in which one or more amino acid residues are modified while maintaining its biological activity.
- a method for producing laminin is not particularly limited, and examples thereof include a method for purifying from a laminin highly expressing cell and a method for producing a recombinant protein.
- a method for producing a laminin fragment is also not particularly limited, and examples thereof include a method of digesting full-length laminin with a proteolytic enzyme such as elastase, fractionating and purifying the target fragment, and a method of producing it as a recombinant protein. Both laminin and laminin fragment are preferably produced as recombinant proteins from the viewpoint of production amount, quality uniformity, production cost, and the like.
- Recombinant laminin and recombinant laminin fragments can be produced by appropriately using known gene recombination techniques.
- a method for producing recombinant laminin and recombinant laminin fragment for example, DNAs encoding full-length proteins or partial proteins of ⁇ chain, ⁇ chain, and ⁇ chain are obtained and inserted into expression vectors, respectively.
- the three types of expression vectors thus obtained can be co-introduced into an appropriate host cell and expressed, and the protein forming the trimer can be purified by a known method. For example, Ido et al.
- the base sequence information of the genes encoding the ⁇ chain, ⁇ chain, and ⁇ chain constituting the main mammalian laminin and the amino acid sequence information of each chain can be obtained from a known database (GenBank, etc.).
- Table 1 shows the accession numbers of the chains constituting laminin for main mammals including humans.
- the base sequence information and amino acid sequence information of laminin constituent chains of various mammals can also be obtained from known databases (GenBank, etc.).
- Laminin E8 is a fragment obtained by removing globular domains 4 and 5 from a C-terminal fragment of ⁇ chain (hereinafter referred to as “ ⁇ chain E8”), a C-terminal fragment of ⁇ chain (hereinafter referred to as “ ⁇ chain E8”) and ⁇
- the C-terminal fragment of the chain (hereinafter referred to as “ ⁇ chain E8”) is a fragment forming a trimer, and the molecular weight of the trimer is about 150 to about 170 kDa.
- the ⁇ chain E8 usually consists of about 770 amino acids, and about 230 amino acids on the N-terminal side are involved in trimer formation.
- the ⁇ chain E8 usually consists of about 220 to about 230 amino acids.
- the ⁇ chain E8 usually consists of about 240 to about 250 amino acids.
- the third glutamic acid residue from the C-terminal part of ⁇ chain E8 is essential for the cell adhesion activity of laminin E8 (Hiroyuki Ido, Aya Nakamura, Reiko Kobayashi, Shunsuke Ito, Shaoliang Li, Sugiko Futaki, andakiKiyotoshi Sekiguchi, “The requirement of the glutamic acid residue at the third position from the carboxyl termini of the laminin ⁇ chains in integrin binding by laminins ”The Journal of Biological Chemistry, 282, 11144-11154, 2007.).
- the cell growth control molecule constituting the modified laminin of the present invention means an extracellular factor necessary for cell culture and amplification. Specifically, (i) it binds to a receptor on the cell surface and binds to a cell scaffold.
- a cell adhesion molecule of an extracellular matrix to be provided or (ii) a molecule associated with growth factor localization control or activity control by binding to a growth factor (referred to herein as a “growth factor binding molecule”) Applicable.
- the growth factor to which the growth factor binding molecule is bound is synonymous with the growth factor, and is not particularly limited as long as it is a substance that promotes cell proliferation, growth, differentiation, and the like.
- EGF Epidermal growth factor
- bFGF basic fibroblast growth factor
- TGF Transforming growth factor
- IGF Insulin-like growth factor
- PDGF Plater-derived growth factor
- VEGF Vasicular endothelial growth factor
- HGF Hepatocyte growth factor
- NGF Neve growth factor
- the cell adhesion molecule constituting the modified laminin of the present invention may be either a molecule involved in adhesion between a cell and an extracellular matrix, or a molecule involved in adhesion between cells, and a membrane protein present in the cell membrane In addition to the extracellular matrix, these are not particularly limited. Further, the cell adhesion molecule constituting the modified laminin of the present invention may be the full length of the cell adhesion molecule or a fragment containing the cell adhesion site of the cell adhesion molecule. Examples of the adhesion molecule include the following (a) to (e), and at least one selected from these is preferable.
- A Cell adhesion molecule that binds to integrin
- b Cell adhesion molecule that binds to membrane-bound proteoglycan
- c Cell adhesion molecule that binds to discoidin domain receptor
- d Cell adhesion molecule that binds to dystroglycan
- Examples of the cell adhesion molecule that binds to integrin include fibronectin, collagen, vitronectin, nephronectin, osteopontin, MAEG, tenascin, SVEP1, TGF- ⁇ 1 ateassociated peptide, and TGF- ⁇ 3 deacidoidate.
- Examples of cell adhesion molecules that bind to membrane-bound proteoglycans include fibronectin, vitronectin, nephronectin, laminin, and the like.
- Examples of cell adhesion molecules that bind to dystroglycan include laminin.
- Suitable cell adhesion molecules constituting the modified laminin of the present invention include, for example, fibronectin, vitronectin, nephronectin, osteopontin, MAEG, TGF- ⁇ 1 latency associated peptide, TGF- ⁇ 3 lateness associatedArgentate -Proteins containing Asp sequences in their molecules, collagen type I, collagen type IV, other collagen molecules, SVEP1, E-cadherin, N-cadherin, P-cadherin and other intercellular adhesion molecules of the cadherin family.
- fragment containing the cell adhesion active site of the cell adhesion molecule examples include, for example, fragments containing the seventh to tenth human fibronectin type III modules (Fusao Kimizuka, Yoichi Ohdate, Yasutoshi Kawase, Tomoko Shimojyo, Yuki Taguchi, Kimikazu Hashino, Shoichi Goto, Hidetaka Hashi, Ikunoshin Kato, Kiyotoshi Sekiguchi, and Koiti Titani, “Role of type III homology repeats in cell adhesive function within the cell-binding domain of fibronenal ist 305 1999.), a fragment containing the 12th to 14th fibronectin type III module (Ri-ichiroh Manabe, beNaoko Oh-e, Toshinaga Maeda, Tomohiko Fukuda, and Kiyotoshi Sekiguchi, “Modulation of cell adhesive activity of fibroneternative spliced EDA segment ”The Journal of Cell Biology
- a linker region in the central part of nephronectin (Yuya Sato, Toshihiko Uemura, Keisuke Morimitsu, Ryoko Sato-Nishiuchi, Ri-ichiroh Manabe, Junichi Takagi, Masashi Yition, alpha8beta1 ”The Journal of Biological Chemistry, 284, 14524-14536, 2009.).
- globular domains 4 and / or 5 of human laminin ⁇ chain can also be suitably used as cell adhesion molecules constituting the modified human laminin of the present invention.
- the method for producing a cell adhesion molecule is not particularly limited, and examples thereof include a method for purification from cells expressing the target cell adhesion molecule and a method for producing a recombinant protein.
- the recombinant protein can be produced by appropriately using a known gene recombination technique.
- Human fibronectin, vitronectin, nephronectin, osteopontin, MAEG, TGF- ⁇ 1, TGF- ⁇ 3, tenascin, type I collagen, type IV collagen, SVEP1, E-cadherin, N-cadherin and P-cadherin are encoded.
- the nucleotide sequence information and amino acid sequence information of the gene to be obtained can be obtained from a known database (GenBank etc.) with the accession numbers described in Table 3, respectively.
- the base sequence information and amino acid sequence information of a gene of a cell adhesion molecule derived from a non-human organism can be obtained from a known database (GenBank, etc.).
- Table 4 shows the base sequence information and amino acid sequence information of a lectin gene derived from a non-human organism among cell adhesion molecules that bind to sugar chains on the cell surface.
- the growth factor-binding molecule constituting the modified laminin of the present invention is not particularly limited as long as it is a molecule that can bind to a growth factor involved in the growth of cultured cells. By chimerizing the growth factor-binding molecule, it becomes possible to capture the growth factor on the substrate surface, to cause the growth factor to act on the cells more efficiently (more physiologically), and to stimulate proliferation.
- the growth factor binding molecule constituting the modified laminin of the present invention may be the full length of the growth factor binding molecule or a fragment containing a growth factor binding site. Examples of the growth factor binding molecule include heparan sulfate proteoglycan.
- heparan sulfate proteoglycans examples include perlecan, agrin, type XVIII collagen, syndecan 1-4, glypican 1-6, and the like.
- growth factor-binding molecules other than heparan sulfate proteoglycans include latent TGF- ⁇ binding protein 1-4.
- the fragment containing the growth factor binding site of the growth factor binding molecule include, for example, perlecan domains I to III (regions from the 22nd valine to the 1676th proline from the N terminus; amino acid sequence information is described in Table 5), Regions containing the first to eighth of the follistatin (FS) domain of agrin (Uwe Winzen, Gregory J.
- Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate / chondroitin sulfate multiple serine-glycine clusters ”The Journal of Biological Chemistry, 27j8, 30106-30114,1142008.).
- the method for producing a growth factor binding molecule is not particularly limited, and examples thereof include a method for purification from cells expressing the target growth factor binding molecule and a method for producing a recombinant protein.
- the recombinant protein can be produced by appropriately using a known gene recombination technique.
- the nucleotide sequence information and amino acid sequence information of the genes encoding human perlecan, agrin, type XVIII collagen, syndecan 1 to 4, glypican 1 to 6, and latent TGF- ⁇ binding protein 1 to 4 are shown in Table 5, respectively. Can be obtained from a known database (GenBank, etc.) with the accession number.
- the modified laminin of the present invention is the N-terminal of the ⁇ chain of the laminin fragment in which the cell growth regulatory molecule (for example, cell adhesion molecule, growth factor binding molecule, etc.) forms a laminin or heterotrimer, the ⁇ chain It may be bonded to at least one position of the C-terminal, the N-terminal of the ⁇ chain, and the N-terminal of the ⁇ chain. Therefore, in the modified laminin of the present invention, the cell growth regulatory molecule may be bound at two sites, may be bound at three sites, or may be bound at four sites. When cell growth control molecules bind to multiple sites, the cell growth control molecules may be one type or two or more types. The cell growth regulatory molecule may be bound to any of the above four sites, but it is preferable that the globular domain 4 and / or 5 of the laminin ⁇ chain is bound to the C-terminus of the ⁇ chain.
- the cell growth regulatory molecule for example, cell adhesion molecule, growth factor binding
- the modified laminin of the present invention can be produced as a recombinant modified laminin by appropriately using a known gene recombination technique.
- a DNA encoding the human laminin ⁇ chain E8 and a DNA encoding the cell growth control molecule are ligated to form human laminin.
- An expression vector is prepared in which a fusion gene encoding a fusion protein in which a cell growth regulatory molecule is bound to the N-terminus of the E8 ⁇ chain is inserted.
- modified laminin in which cell growth control molecules are bound to other sites and a modified laminin in which cell growth control molecules are bound to a plurality of locations can also be produced according to this.
- the modified laminin of the present invention may be obtained by chemically binding a cell growth regulatory molecule to at least one of the N-terminus of the ⁇ chain, the C-terminus of the ⁇ -chain, the N-terminus of the ⁇ -chain, and the N-terminus of the ⁇ -chain. Good.
- the modified laminin of the present invention has a high cell adhesion activity and / or proliferation stimulating activity, and can be provided as a highly pure and homogeneous protein, and thus is very useful as an extracellular matrix for cultured cells, particularly cultured stem cells. is there.
- the modified laminin of the present invention as a human-derived modified laminin, human stem cells can be cultured in a feeder-free and xeno-free environment, and highly safe human stem cells that can be applied to regenerative medicine are provided. be able to.
- the present invention provides a culture method for culturing mammalian cells in the presence of the modified laminin of the present invention. Since the modified laminin of the present invention has a high cell adhesion activity and / or proliferation stimulating activity, cells that have been conventionally cultured using feeder cells can be used as an extracellular matrix that serves as a scaffold for mammalian cells. Can be cultured without using feeder cells.
- the culture method of the present invention can be applied to any mammalian cell culture, but is preferably applied to stem cell culture.
- Stem cells mean cells having self-replicating ability and pluripotency, and include somatic stem cells, pluripotent stem cells, and the like.
- somatic stem cells include neural stem cells, mesenchymal stem cells, and hematopoietic stem cells.
- pluripotent stem cells include ES cells (embryonic stem cells), iPS cells (artificial pluripotent stem cells), mGS cells (pluripotent germ stem cells), and fusion cells of ES cells and somatic cells. More preferred are pluripotent stem cells, and more preferred are ES cells and iPS cells.
- Mammals are not particularly limited, and examples include humans, mice, rats, cows, and pigs. Of these, humans are preferable. That is, the culture method of the present invention is preferably used for culturing human stem cells. When human stem cells are cultured using the culture method of the present invention, it is preferable to use human-derived modified laminin.
- the method of culturing in the presence of the modified human laminin may be a method of culturing cells using a medium supplemented with the modified laminin of the present invention, or a method of culturing cells using a culture substrate coated with the modified laminin of the present invention. But you can.
- the modified laminin may be added to the medium in advance, or the modified laminin may be added to the medium at the time of use.
- the amount of the modified laminin to be added is not particularly limited, but a concentration of about 0.03 to about 25 ⁇ g / cm 2 is preferable, more preferably about 0.06 to about 10 ⁇ g / cm 2 with respect to the culture area of the incubator used for culture. 2 , more preferably from about 0.38 to about 3.8 ⁇ g / cm 2 .
- the culture method of the present invention a culture method when culturing human stem cells in the presence of human-derived modified laminin will be described, but the culture method of the present invention is not limited thereto, It can also be suitably used for culturing mammalian cells other than humans.
- the medium to be used is not particularly limited, but a synthetic medium is preferred, and a synthetic medium containing no non-human biological component (xenofree) is particularly preferred.
- xenofree non-human biological component
- TeSR2 is a xeno-free medium.
- media described in the following documents (i) to (v) can also be suitably used.
- Method 1 Add 0.25% trypsin / DMEM-F12 (eg 1 ml / 60 mm dish) to a culture dish (days 3-5) of human iPS cells co-cultured with feeder cells (eg MEF) at 37 ° C. Incubate for 2-3 minutes and wash the culture dish with DMEM-F12 to remove feeder cells.
- the cell suspension obtained by physically detaching whole cells by adding the culture solution was passed through a BD Falcon cell strainer 100 ⁇ m (BD Falcon # 352460), and then the strainer was washed to isolate only human iPS cell colonies, to recover.
- Method 2 Cell detachment solution (for example, ES / iPS cell detachment solution (Reprocell RCHETP002), 1 mg / ml dispase / DMEM) in culture dishes (3-5 days) of human iPS cells co-cultured with feeder cells (for example, MEF) -F12, 10 mg / ml collagenase IV / DMEM-F12, etc.) is added (for example, 1 ml / 60 mm dish) and incubated at 37 ° C. for 5 minutes to detach human iPS cells and MEF. The cells are transferred to a 15 ml centrifuge tube, and about 10 ml of the culture solution is added to suspend the cells. Then, the tube is allowed to stand for 5 minutes to precipitate only the colonies. The supernatant is removed, and the same operation is repeated twice or more to precipitate and collect only human iPS cell colonies.
- feeder cells for example, MEF
- the colonies of collected human iPS cells are dispersed into single cells.
- the method for dispersing the cells in a single cell is not particularly limited, and examples thereof include a trypsin treatment method and a method of crushing colonies by flushing the culture solution several times using a P-1000 pipetteman or the like.
- After being dispersed in a single cell it is suspended in an appropriate culture medium (for example, TeSR2) and seeded on a culture dish coated with human-derived modified laminin (for example, 1.0 ⁇ g / cm 2 ). Cultivation is performed under CO 2 concentration conditions compatible with the culture medium used, and the culture medium is exchanged every day.
- subculture can be performed by a method of seeding human iPS cells while maintaining an appropriately sized colony form as in the conventional method, and human iPS cells are converted into single cells.
- the state of being dispersed in a single cell does not require that all cells in the cell suspension are dispersed in a single cell.
- the state in which about 10 or more cells adhered are contained in the cell suspension is also included in the state of being dispersed in a single cell.
- TrypLE Select (trade name, Invitrogen # 12563011) is added to a culture dish in which human iPS cells are cultured (for example, 1 ml / 100 mm dish), and is incubated at 37 ° C. for 5 minutes.
- a colony of human iPS cells is crushed by flushing the culture solution several times using a P-1000 pipetteman or the like, and dispersed into single cells.
- Suspend cells by adding culture medium and collect in a centrifuge tube.
- the cells were suspended in fresh culture solution and coated with human-derived modified laminin (for example, 1.0 ⁇ g / cm 2 ).
- human-derived modified laminin for example, 1.0 ⁇ g / cm 2 .
- a culture dish is seeded with human iPS cells dispersed in a single cell at a seeding density of, for example, about 40,000 cells / cm 2 .
- Cultivation is performed under CO 2 concentration conditions compatible with the culture medium used, and the culture medium is exchanged every day.
- the enzyme solution is removed, the culture solution is added, and the culture solution is flushed several times using, for example, a P-1000 pipetteman or the like, so that human iPS cells are crushed small enough to maintain about 50 to about 100 colonies.
- the cell suspension is collected in a centrifuge tube, and after centrifugation (200 ⁇ g, 3 minutes) and washing with the same culture solution are repeated twice, the cells are suspended in a fresh culture solution, and human-derived modified laminin is added.
- a culture dish coated eg 1.5 ⁇ g / cm 2
- Cultivation is performed under CO 2 concentration conditions compatible with the culture medium used, and the culture medium is exchanged every day.
- the present invention provides a method for establishing iPS cells in the presence of the modified laminin of the present invention.
- the iPS cell establishment method of the present invention only needs to include a step of bringing a nuclear reprogramming substance into contact with a somatic cell in the presence of the modified laminin of the present invention. Furthermore, it is preferable to include a step of culturing somatic cells that have been contacted with a nuclear reprogramming substance in the presence of the modified laminin of the present invention.
- iPS cells can be established according to the procedures described in (vi) to (xiii) below, for example.
- iPS cells that are inferior to ES cells in pluripotency can be produced in humans and mice.
- the specific factor is defined as “nuclear reprogramming substance” in the present invention, and is introduced into a somatic cell or brought into contact with a somatic cell together with a factor for improving the establishment efficiency of an iPS cell.
- a substance (s) capable of inducing iPS cells from a protein it may be composed of any substance such as a protein factor or a nucleic acid encoding the same (including a form incorporated in a vector) or a low molecular weight compound. Good.
- the nuclear reprogramming substance is a protein factor or a nucleic acid encoding the same
- the following combinations are preferably exemplified (in the following, only the name of the protein factor is described).
- c-Myc can be replaced with T85A (active mutant), L-Myc.) (3) Oct3 / 4, Klf4, c-Myc, Sox2, Fbx15, Nanog, ERas, TcelI (4) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, SV40 Large T antigen (hereinafter SV40LT) (5) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, HPV16 E6 (6) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, HPV16 E7 (7) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, HPV6 E6, HPV16 E7 (8) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, Bmil (See above, WO 2007/069666 (however, regarding the substitution of Sox2 to Sox18 and the substitution of Klf4 to Klf1 or Kl
- Sox2 Sox1, Sox3, Sox15, Sox17, Sox18
- Sox7 Sox7
- Glis family members Glis2, Glis3, etc. can be used instead of Glis1.
- L-Myc or Lin28B can be used instead of c-Myc or Lin28, respectively.
- a combination that does not fall under the above (1) to (26) but includes all of the components in any of them and further includes any other substance is also included in the category of “nuclear reprogramming substance” in the present invention. Can be included.
- the condition that the somatic cells subject to nuclear reprogramming have endogenously expressed some of the components in any of (1) to (26) above at a sufficient level for nuclear reprogramming.
- a combination of only the remaining components excluding the component can also be included in the category of “nuclear reprogramming substance” in the present invention.
- at least one, preferably two or more, more preferably three or more selected from Oct3 / 4, Sox2, Klf4, L-Myc, Lin28 and Glis1 are preferred nuclear reprogramming substances. Take as an example.
- Mouse and human cDNA sequence information for each of the above proteinaceous factors can be obtained by referring to NCBI accession numbers described in WO 2007/069666 (Nanog is described as “ECAT4” in this publication)
- mouse and human cDNA sequence information of Lin28, Lin28B, Esrrb, Esrrg, L-Myc, and Glis1 can be obtained by referring to NCBI accession numbers listed in Table 6, respectively). These cDNAs can be easily isolated.
- the introduction of a nuclear reprogramming substance capable of inducing iPS cells into a somatic cell can be carried out using a known method for introducing a protein into a cell when the substance is a protein factor.
- a method using a protein introduction reagent examples include a method using a protein introduction reagent, a method using a protein introduction domain or a cell-permeable peptide fusion protein, and a microinjection method.
- electroporation method semi-intact cell method (Kano, F. et al. Methods in Molecular Biology, Vol. 322, 357-365 (2006)), introduction method using Wr-t peptide (Kondo, E. et al. Protein introduction methods such as Mol. Cancer Ther.
- the nuclear reprogramming substance in the form of a nucleic acid encoding it rather than as the protein factor itself.
- the nucleic acid may be DNA or RNA, or may be a DNA / RNA chimera.
- the nucleic acid may be double-stranded or single-stranded.
- the nucleic acid is double stranded DNA, in particular cDNA.
- the nuclear reprogramming substance cDNA is inserted into an appropriate expression vector containing a promoter that can function in a host somatic cell.
- expression vectors examples include retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes viruses, Sendai virus and other viral vectors, animal cell expression plasmids (eg, pA-11, pxT1, pRc / CMV, pRc / RSV). , PcDNAI / Neo) and the like.
- the kind of vector to be used can be suitably selected according to the use of the iPS cell obtained.
- adenovirus vectors, plasmid vectors, adeno-associated virus vectors, retrovirus vectors, lentivirus vectors, Sendai virus vectors and the like can be used.
- the nucleic acid (reprogramming gene) that is a nuclear reprogramming substance may be incorporated on a separate expression vector, or two or more, preferably 2-3 types of genes may be incorporated into one expression vector. It is preferable to select the former when using a retrovirus or lentiviral vector with high gene transfer efficiency, and the latter when using a plasmid, adenovirus, episomal vector, or the like. Furthermore, an expression vector incorporating two or more types of genes and an expression vector incorporating only one gene can be used in combination.
- the present invention provides a method for rapidly expanding stem cells.
- the rapid expansion method of the present invention includes a step of dispersing stem cells into single cells, and a step of culturing the stem cells dispersed in single cells in the presence of the modified laminin of the present invention. What is necessary is just to seed the dispersed stem cells at a density of about 2 ⁇ 10 4 to about 20 ⁇ 10 4 cells / cm 2 .
- the seeding density is more preferably about 3 ⁇ 10 4 to about 10 ⁇ 10 4 cells / cm 2 , and further preferably about 4 ⁇ 10 4 to about 5 ⁇ 10 4 cells / cm 2 .
- the adhesion efficiency when the monodispersed stem cells are seeded at the above cell density is very low.
- a significantly high adhesion efficiency is obtained. Then, since it proliferates vigorously, stem cells can be proliferated at a remarkably higher rate than the conventional method.
- the culture method can be performed according to the description of the culture method of the present invention.
- the rapid expansion method for stem cells of the present invention is preferably applied to pluripotent stem cells such as ES cells and iPS cells, and more preferably to ES cells. Further, it is preferably applied to human pluripotent stem cells, and more preferably applied to human ES cells.
- the method for rapidly expanding stem cells of the present invention is applied to human stem cells, it is preferable to use human-derived modified laminin.
- the present invention provides a method for isolating a stem cell-derived clone from a stem cell.
- the single cell-derived clone isolation method of the present invention includes a step of dispersing stem cells into single cells, and a step of culturing the stem cells dispersed in single cells in the presence of the modified laminin of the present invention. What is necessary is just to form the colony derived from a single cell.
- a single cell-derived clone separation method of the present invention a single cell-derived clone of a stem cell, which was difficult in a conventional culture system, can be formed and separated, and uniform stem cells can be easily obtained. It becomes possible.
- a method for forming a single cell-derived colony and isolating a single cell-derived clone is not particularly limited.
- a known limiting dilution method can be suitably used.
- a cell density and a culture substrate to be used are appropriately selected according to the method to be used, and human stem cells dispersed in a single cell are seeded and cultured.
- the culture method can be performed according to the description of the culture method of the present invention.
- the single cell-derived clone separation method for stem cells of the present invention is preferably applied to pluripotent stem cells such as ES cells and iPS cells, and more preferably to ES cells. Further, it is preferably applied to human pluripotent stem cells, and more preferably applied to human ES cells.
- the method for isolating a stem cell-derived clone of the present invention is applied to human stem cells, it is preferable to use human-derived modified laminin.
- the present invention provides a method for culturing single cells of stem cells.
- the single cell culture method of the present invention includes a step of dispersing stem cells into single cells, and a step of culturing the stem cells dispersed in single cells in the presence of the modified laminin of the present invention. What is necessary is just to maintain in the state of a single cell, without making it proliferate. Stem cells that have formed colonies may have different cell states in the periphery of the colony and in the interior of the colonies. However, according to the single cell culture method of the present invention, cells do not form colonies, and thus stem cells that have a uniform state. Thus, improvement in differentiation induction efficiency can be expected.
- the cell density is appropriately selected according to the culture substrate to be used, seeded with stem cells dispersed in the single cells, and before the cells proliferate. It is preferable to use the cells for other purposes.
- the time that can be maintained in the state of a single cell may be extended by using a culture solution that does not contain a growth factor or a culture solution in which the growth factor is reduced.
- the stem cell single cell culture method of the present invention is preferably applied to pluripotent stem cells such as ES cells and iPS cells, and more preferably to ES cells. Further, it is preferably applied to human pluripotent stem cells, and more preferably applied to human ES cells. When applying the stem cell single cell culture method of the present invention to human stem cells, it is preferable to use human-derived modified laminin.
- the present invention provides a culture substrate coated with the modified laminin of the present invention.
- the cell cultured using the culture substrate of the present invention is not particularly limited, and any cell that can be cultured can be cultured using the culture substrate of the present invention.
- Stem cells are preferred.
- Stem cells include somatic stem cells, pluripotent stem cells and the like.
- somatic stem cells include neural stem cells, mesenchymal stem cells, and hematopoietic stem cells.
- pluripotent stem cells include ES cells (embryonic stem cells), iPS cells (artificial pluripotent stem cells), mGS cells (pluripotent germ stem cells), and fusion cells of ES cells and somatic cells.
- pluripotent stem cells More preferred are pluripotent stem cells, and more preferred are ES cells and iPS cells. Mammals include humans, mice, rats, cows, pigs and the like. Of these, humans are preferable.
- the culture substrate of the present invention is very useful when culturing cells that have been conventionally cultured using feeder cells without using feeder cells.
- the method for producing the culture substrate of the present invention is not particularly limited, and any method may be used as long as it can coat a known incubator with the modified laminin of the present invention.
- physiological salt of the above-described modified laminin of the present invention adjusted to neutral pH with an appropriate solvent such as PBS, physiological saline, trishydroxymethylaminomethane or 4- (2-hydroxyethyl) -1-piperazine ethanesulfonic acid.
- the diluted laminin is coated on the surface of the incubator by diluting with water or the like, and adding this solution to a suitable incubator and allowing to stand at about 4 to 37 ° C. for about 1 to 12 hours.
- a culture substrate can be produced.
- the incubator is not limited as long as it can be used for culturing mammalian cells.
- a glass or plastic petri dish, flask, multiwell plate, culture slide, microcarrier, polyvinylidene fluoride membrane, etc. A polymer film etc. are mentioned.
- Coating concentration of the modified laminin is not particularly limited, but is preferably from about 0.03 to about 25 [mu] g / cm 2, more preferably from about 0.06 to about 10 [mu] g / cm 2, from about 0.38 to about 3.8 ⁇ g / cm 2 is more preferable. Since the culture substrate of the present invention uses modified laminin, a large number of human stem cells can adhere and proliferate even at a low coating concentration as compared with the case where a conventional matrigel is coated.
- the culture substrate of the present invention may be coated with a single modified laminin or may be coated with a plurality of different modified laminins.
- components other than the modified laminin may be coated.
- serum components, extracellular matrix molecules, growth factors, differentiation inducing factors, morphogenic factors (morphogens) and the like can be mentioned.
- non-biological components such as a synthetic polymer gel (synthetic polymer) may be coated.
- the culture substrate of the present invention is preferably coated with human-derived modified laminin.
- the components other than the modified laminin are preferably human-derived components.
- the culture substrate of the present invention coated with human-derived modified laminin maintains human stem cells while maintaining pluripotency in a culture environment that does not use feeder cells normally used for human stem cell culture (feeder-free) It becomes possible to culture.
- human stem cells are cultured on feeder cells such as mouse embryonic fibroblasts (MEF) whose growth has been stopped by X-ray irradiation or mitomycin C treatment in order to maintain clonal proliferation and undifferentiation.
- feeder cells such as mouse embryonic fibroblasts (MEF) whose growth has been stopped by X-ray irradiation or mitomycin C treatment in order to maintain clonal proliferation and undifferentiation.
- a culture system for co-culturing stem cells such a culture system that does not use feeder cells is feeder-free.
- a medium from which xenogeneic components are excluded is used, human stem cells can be cultured under culture conditions that are completely free of xenogeneic components (Xeno-Free). It is possible to provide highly safe human stem cells that are very unlikely to express virulence. Examples of the xenofree medium include TeSR2 (trade name, STEMCELL TECHNOLOGIES).
- Example 1 Production of modified human laminin
- recombinant human laminin 511E8 (Hereinafter referred to as “rhLM511E8”) was prepared by adding human laminin ⁇ 1 chain globular domain 4-5 (hereinafter referred to as “human laminin ⁇ 1 chain LG45”) to the C-terminal part of E8 of human laminin ⁇ 5 chain.
- PCR was carried out using the following three types of primer sets, and a 6 ⁇ His tag ( Three types of pBluescript KS (+) each having a DNA sequence encoding HHHHHH), a DNA sequence encoding HA (hemagglutinin) tag (YPYDVPDYA), or a DNA sequence encoding FLAG tag (DYKDDDDK) were prepared.
- a plasmid containing the full-length base sequence of ⁇ 5 chain, ⁇ 1 chain, and ⁇ 1 chain (Hiroyuki Ido, Kenji Harada, Sugiko Futaki, Yoshitaka Hayashi, Ryoko Nishiuchi, Yuko Natsuka, Shaoliang Li, Yoshinao Wada, Ariana C.
- PCR was performed using the following primers to amplify regions corresponding to ⁇ 5 (Ala 2534 -Ala 3327 ), ⁇ 1 (Leu 1561 -Leu 1786 ), and ⁇ 1 (Asn 1362 -Pro 1609 ) of each strand.
- the amplified DNA fragment was inserted into the EcoRV site of the multicloning site of pBluescript KS (+) to which the tag sequence was added, and then the amplified DNA fragment including the sequence encoding the 5′-side tag was subjected to restriction enzymes EcoRI and HindIII.
- an expression vector pSecTag2B for mammalian cells (Invitrogen, having a DNA sequence encoding the mouse Ig- ⁇ chain V-J2-C signal peptide internally), and a human ⁇ 5 chain E8 fragment (N-terminal) 6 ⁇ His tag on the side), human ⁇ 1 chain E8 fragment (including the HA tag on the N-terminal side), and human ⁇ 1 chain E8 fragment (including the FLAG tag on the N-terminal side), respectively.
- the amplified product was digested with the restriction enzyme AscI and inserted into the AscI-PmeI site of the human laminin ⁇ 5 chain E8 expression vector to prepare a human laminin ⁇ 1 chain LG45 fusion human laminin ⁇ 5 chain E8 fragment expression vector.
- PCR was performed using a human laminin ⁇ 5 chain E8 fragment expression vector as a template and the following primers to amplify 754 base pairs at the 3 ′ side of the ⁇ 5 chain E8 fragment.
- the sequence used for extension PCR is added to the 5 ′ side of the primer of SEQ ID NO: 14.
- Human laminin ⁇ 5 chain partial fragment amplification primer 5′-CAATGATCTGGAGCTGGCCGACGCCTACTACCTG-3 ′ (forward, SEQ ID NO: 13) 5'-CTCTGCATCAGGCCCCAGGCCCGGGGTC-3 '(reverse, SEQ ID NO: 14)
- a plasmid containing the full-length base sequence of human laminin ⁇ 1 chain (Hiroyuki Ido, Kenji Harada, Yoshiko Yagi, and Kiyotoshi Sekiguchi, “Probing the integrin-binding site within the globular domain of laminin-511 with the function-blocking monoclonal antibody 4C7 . ”, Matrix Biology, 25 (2), 112-117, 2006) was used as a template to perform PCR using the following primers to amplify a region corresponding to the human laminin ⁇ 1 chain LG45 site (Asp 2684 -Ser 3075 ) .
- the obtained two kinds of DNA fragments were ligated and amplified by extension PCR using the following primers to obtain DNA fragments encoding the C-terminal part of human laminin ⁇ 5 chain E8 and the human laminin ⁇ 1 chain LG45 site.
- the amplified DNA was digested with the restriction enzyme AscI and inserted into the AscI-PmeI site of the human laminin ⁇ 5 chain E8 expression vector to prepare a human laminin ⁇ 1 chain LG45 fusion human laminin ⁇ 5 chain E8 fragment expression vector.
- the amplified product is digested with restriction enzymes NheI and NotI, and inserted into the corresponding site of mammalian cell expression vector pSecTag2B (Invitrogen, which has a gene sequence encoding a mouse Ig- ⁇ chain VJ2-C signal peptide endogenously). Then, an expression vector of FNIII7-10 fusion human laminin ⁇ 1E8 fragment expression vector was prepared.
- PCR was performed using a human laminin ⁇ 1 chain E8 fragment expression vector as a template and the following primers, and regions corresponding to mouse Ig- ⁇ chain V-J2-C signal peptide-FLAG tag and ⁇ 1 chain E8 fragment were respectively represented. Amplified.
- arrangement used for extension PCR is added to the 5 'side of the primer of sequence number 18 and 19.
- human fibronectin expression vectors Hiroki Akamatsu, Keiko Ichihara-Tanaka, Keiichi Ozono, Wataru Kamiike, Hikaru Matsuda, and Kiyotoshi Sekiguchi, “Suppression of Transformed Phenotypes of Human Fibrosarcoma Cells by Overexpression of Recombinant Fibronectin”, Cancer Research, 56, 4541-4546, 1996) was used as a template, and PCR was performed using the following primers to amplify a region corresponding to FNIII 7 to 10 (Pro 1173 -Arg 1539 ). In addition, the sequence used for extension PCR is added to the 5 ′ side of the primers of SEQ ID NOs: 21 and 22.
- the three types of DNA fragments obtained were ligated and amplified by extension PCR using the following primers to encode mouse Ig- ⁇ chain V-J2-C signal peptide-FLAG tag-FNIII7-10- ⁇ 1 chain E8 A DNA fragment was obtained.
- the amplified DNA was digested with restriction enzymes NheI and NotI and inserted into the corresponding site of mammalian cell expression vector pSecTag2B (Invitrogen) to prepare an expression vector for FNIII7-10 fusion human laminin ⁇ 1E8 fragment.
- each chain expression vector 150 ⁇ g of each chain expression vector was simultaneously transferred to 300 ml of 293-F cells (1.0 ⁇ 10 6 cells / ml) using transfection reagent 293fectin (trade name, Invitrogen) and Opti-MEM (trade name, Invitrogen). After infecting and culturing for 72 hours, the culture solution was collected. The culture solution was centrifuged at 1000 ⁇ g for 10 minutes, and the supernatant was further centrifuged at 15,000 ⁇ g for 30 minutes to remove cells and insoluble matters. 10 ml of Ni-NTA agarose (Qiagen) was added to the culture supernatant and incubated overnight to adsorb the target protein.
- 293fectin trade name, Invitrogen
- Opti-MEM trade name, Invitrogen
- Ni-NTA agarose was recovered, washed with TBS ( ⁇ ) (Tris buffered saline without Ca and Mg) and 10 mM imidazole / TBS ( ⁇ ) and then eluted with 200 mM imidazole / TBS ( ⁇ ).
- TBS Tris buffered saline without Ca and Mg
- ⁇ 10 mM imidazole / TBS
- ⁇ 200 mM imidazole / TBS
- the amount of protein in the elution fraction was confirmed by the absorbance of A280, 3 ml of ANTI-FLAG M2 affinity Gel (Sigma) was added to the fraction from which the target protein was eluted, and the mixture was swirled at 4 ° C. overnight.
- the gel was transferred to a polyprep column (Bio-Rad, # 731-1550B04), washed with TBS ( ⁇ ), and eluted with TBS ( ⁇ ) containing 100 ⁇ g / ml FLAG peptide (Sigma, # F3290). The elution fraction was confirmed by silver staining, and the eluted fractions were combined and dialyzed against PBS ( ⁇ ) (phosphate buffered physiological saline). The purified product after dialysis was sterilized by passing through a 0.22 ⁇ m disc syringe filter (Millipore, # SLGV033RS) and stored at ⁇ 80 ° C.
- PBS phosphate buffered physiological saline
- Electrophoresis was performed under reducing conditions using a buffer consisting of 25 mM Tris, 192 mM glycine, and 0.1% sodium dodecyl sulfate according to the Laemmli method.
- Quick-CBB WAKO, # 299-50101 was used for protein staining.
- Example 2 Comparison of concentration-dependent adhesion efficiency of human iPS cells to various extracellular substrates
- Human iPS cell The human iPS cell used the strain
- tic JCRB13311
- the solution containing the tic cell colony and mouse feeder cells was passed through a BD Falcon cell strainer 100 ⁇ m, and the tic cell colony was separated by washing the strainer.
- the remaining colonies were recovered with TeSR2 (trade name, STEMCELL TECHNOLOGIES), which is a xenofree medium, finely crushed with a P-1000 pipetman, resuspended in TeSR2, and seeded in an incubator coated with Matrigel.
- TeSR2 trade name, STEMCELL TECHNOLOGIES
- the culture medium was changed every day under conditions of 37 ° C. and 5% CO 2 , and expanded culture was performed until 4-5 days. Cells expanded in this way were subjected to experiments.
- the Matrigel solution was added to the plate in a range of 0.1 to 30 ⁇ g / cm 2 , and the Plus # 1 laminin E8 solution and the Plus # 2 laminin E8 solution were added in the range of 0.0038 to 3.8 ⁇ g / cm 2 .
- Example 3 Subculture of human iPS cells in an incubator coated with various extracellular substrates (I)]
- Human iPS cells Human iPS cells are 32R1 (Masato Nakagawa, Nanako Takizawa, Megumi Narita, Tomoko Ichisaka, Shinya Yamanaka, “Promotion of direct reprogramming by transformation-deficient Myc.”, Proceedings of the National Academy of Sciences, 107 ( 32), 14152-14157, 2010).
- 32R1 cells were maintained on MSTO mouse feeder cells (Kazutoshi Takahashi, Koji Tanabe, Mari Ohnuki, Megumi Narita, Tomoko Ichisaka, Kiichiro Tomoda, Shinya Yamanaka, “Induction of pluripotent stem cells from adult human fibroblasts by defined factors.”, Cell, 131 (5), 861-872, 2007).
- Example 4 Binding activity of Plus # 2 laminin E8 to recombinant human ⁇ 5 ⁇ 1 integrin or ⁇ 6 ⁇ 1 integrin]
- Experimental method The binding activity of Plus # 2 laminin E8, rhLM511E8 or fibronectin and recombinant human ⁇ 5 ⁇ 1 integrin or ⁇ 6 ⁇ 1 integrin was measured.
- Fibronectin is prepared according to the method of Sekiguchi et al. (Kiyotoshi Sekiguchi and Sen-itiroh Hakomori, “Domain structure of human plasma fibronectin. Differences and similarities between human and hamster fibronectins.”, The Journal of Biological Chemistry, 258, 3967-3973, 1983).
- Recombinant human ⁇ 5 ⁇ 1 integrin was prepared using an expression vector prepared by Takagi et al. (Junichi Takagi, Harold P. Erickson, and Timothy A. Springer, “C-terminal opening mimics 'inside-out' activation of integrin alpha5beta1.” , Nature structural & molecular biology, 8 (5), 412-416, 2001). This recombinant human ⁇ 5 ⁇ 1 integrin is composed of an ⁇ 5 subunit and an extracellular domain of the ⁇ 1 subunit.
- a sequence consisting mainly of an acidic amino acid residue and a hydrophobic amino acid residue is present at the C-terminal part of ⁇ 5, and a base is mainly present at the C-terminal part of ⁇ 1.
- a sequence consisting of a hydrophobic amino acid residue and a hydrophobic amino acid residue is added.
- a FLAG tag is added to the C-terminal part of ⁇ 5, and a 6 ⁇ His tag is added to the C-terminal part of ⁇ 1.
- Recombinant human integrin ⁇ 6 ⁇ 1 is produced by the method of Ido et al.
- Tris buffered saline containing 1% (w / v) bovine serum albumin and 0.02% (v / v) Tween-20 10 nM recombinant human ⁇ 5 ⁇ 1 or ⁇ 6 ⁇ 1 integrin was reacted at room temperature for 3 hours in the presence of 1 mM Mn 2+ .
- Tris buffered saline containing 1 mM Mn 2+ , 0.1% (w / v) bovine serum albumin and 0.02% (v / v) Tween-20 hereinafter “1 mM Mn 2+ / 0.
- the wells were washed three times with 1% BSA / TBS-T 0.02 ), and then a biotinylated rabbit polyclonal antibody that recognizes the dimerization site of the recombinant integrin was incubated at room temperature in the presence of 1 mM Mn 2+. The reaction was performed for 3 hours. The wells were washed three times with 1 mM Mn 2+ /0.1% BSA / TBS-T 0.02 , and then HRP-labeled streptavidin was reacted at room temperature for 15 minutes in the presence of 1 mM Mn 2+ .
- the wells were washed three times with 1 mM Mn 2+ /0.1% BSA / TBS-T 0.02 , and then an o-phenylenediamine / H 2 O 2 solution was added to perform a color reaction. To stop the reaction, 2.5 MH 2 SO 4 was used. For quantification of the color intensity, the absorbance at a wavelength of 490 nm was measured using a multiplate reader.
- Example 5 Monodisperse culture of human ES cells in an incubator coated with various extracellular substrates
- Human ES cell H9 strain purchased from National Stem Cell Bank was used as the human ES cell.
- As feeder cells SNL cells treated with mitomycin C to stop cell division (McMahon, AP & Bradley, A. Cell 62, 1073-1085 (1990)) were used to repopulate H9 cells on feeder cells. went.
- a primate ES cell culture medium (ReproCELL) was used as the medium, and co-culture was performed.
- the X0.5 TrypLE Select added previously was removed, 3 ml / well of maintenance culture medium was added, and then the cells were detached with a cell scraper. (3-4) Cell Culture After removing feeder cells, 13,000 monodispersed H9 cells were seeded on the previously prepared coating plate (6-well plate), and 37 ° C. CO 2 5% Single dispersion culture was performed in an incubator. The next day, the medium was replaced with a maintenance culture medium. The medium was changed every other day, and every day from around the 6th and 7th days after the start of the culture.
- FIG. 5 shows the results of H9 cell monodisperse culture in an incubator coated with various extracellular substrates, 7 days of culture, and then staining the grown cell colonies with alkaline phosphatase (ALP). It was.
- Example 6 Subculture of human iPS cells in an incubator coated with various extracellular substrates (II)]
- Human iPS cells In human iPS cells, 4 genes of Oct3 / 4, KLF4, SOX2, and L-MYC are introduced into adult skin-derived fibroblasts (aHDF-Slc7al) using a retrovirus.
- 32R1 cells (Masato Nakagawa, Nanako Takizawa, Megumi Narita, Tomoko Ichisaka, Shinya Yamanaka, “Promotion of direct reprogramming by transformation-deficient Myc.”, Proceedings of the National Academy of Sciences, 107 (32), 14152- 14157, 2010).
- human perlecan expression vectors (Shaoliang Li, Chisei Shimono, Naoko Norioka, Itsuko Nakano, Tetsuo Okubo, Yoshiko Yagi, Maria Hayashi, Yuya Sato, Hitomi Fujisaki, Shunji Hattori, Nobuo Sugiura, Koji Kimata and Kiyotoshi Sekiguchi, “Activin A Binds to Perlecan through Its Pro-region That Has Heparin / Heparan Sulfate Binding Activity ”, Journal of Biological Chemistry, 285 (47), 36645-36655, 2010), and PCR using the following primers and Pln-D1 A region corresponding to / 2/3 (Gly 25 -Glu 1680 ) was amplified.
- a restriction enzyme HindIII recognition sequence is added to the 5 ′ side of the primer.
- the obtained DNA fragment was digested with the restriction enzyme HindIII and inserted into the site of the human laminin ⁇ 1 chain E8 fragment expression vector to prepare a Pln-D1 / 2/3 fusion human laminin ⁇ 1 chain E8 fragment expression vector.
- (xiv) Primer for amplification of Pln-D1 / 2/3 sequence 5′-ACGAAGCTTGGGCTGAGGGCATACGATGGC-3 ′ (forward, SEQ ID NO: 23) 5'-ATAAAGCTTCTCGACCACCAGTGGGGCTTGG-3 '(reverse, SEQ ID NO: 24)
- FIG. 6 shows the state of human iPS cells before passage on the seventh day from the start of culture. 6, Matrigel coat (Matrigel (coating amount: 30 ⁇ g / cm 2 )), rhLM511E8 coat (E8 in the figure), Plus # 1 laminin E8 coat (E8plus # 1 in the figure), lower stage From the left, Plus # 2 laminin E8 coat (E8plus # 2 in the figure) and Plus # 3 laminin E8 coat (E8plus # 3 in the figure). In an incubator coated with various extracellular substrates, engraftment of 32R1 cells was confirmed.
- Matrigel coat Matrigel (coating amount: 30 ⁇ g / cm 2 )
- rhLM511E8 coat E8 in the figure
- Plus # 1 laminin E8 coat E8plus # 1 in the figure
- lower stage From the left Plus # 2 laminin E8 coat (E8plus # 2 in the figure)
- Plus # 3 laminin E8 coat E8plus #
- FIG. 7 shows the results of immunostaining in human iPS cells that had been subcultured for 10 passages using an incubator coated with Plus # 1 laminin E8 or Plus # 2 laminin E8.
- the upper two rows are results using an incubator coated with Plus # 1 laminin E8 (LN511E8plus # 1 in the drawing), and the lower two rows are Plus # 2 laminin E8 (LN511E8plus # 2 in the drawing). It is the result using the incubator coated with.
- Each upper phase difference image (PH) is shown, and the lower row is an immunofluorescence image (FL).
- Example 7 Monodisperse culture of human iPS cells in an incubator coated with various extracellular substrates
- Human iPS cells The same 32R1 cells as in Examples 3 and 6 were used.
- Extracellular matrix In the same manner as in Example 5, Plus # 1 laminin E8, Plus # 2 laminin E8, full-length laminin 511 and Matrigel were used.
- Example 3 Culture of human iPS cells The plate was coated in the same manner as in Example 3. In the same manner as in Example 6, the feeder cells were removed, and 13,000 32R1 cells dispersed in a single manner were seeded on a previously prepared coating plate (6-well plate), and single in a 37 ° C. CO 2 5% incubator. Dispersion culture was performed. The next day, the medium was replaced with a maintenance culture medium. The medium was changed every other day, and every day from around the 6th and 7th days after the start of the culture.
- FIG. 8 shows the results of performing single dispersion culture of 32R1 cells in an incubator coated with various extracellular substrates, culturing for 7 days, and then staining the grown cell colonies with alkaline phosphatase (ALP). It was.
- no coat from the left on the upper stage (None in the figure), Matrigel coat (Matrigel in the figure), full length laminin 511 coat (LN511FL in the figure), Plus # 1 laminin E8 coat from the left in the lower stage (LN511E8plus in the figure) # 1) Plus # 2 laminin E8 coat (LN511E8 plus # 2 in the figure).
- Example 8 Establishment of human iPS cells
- Human iPS cells were used using an incubator coated with Plus # 1 laminin E8 or Plus # 2 laminin E8, instead of using human iPS cell lines established in advance as in Examples 6 and 7 above. Tried to establish. The coating concentration was 0.5 ⁇ g / cm 2 .
- adult skin-derived fibroblasts HDF1388 cells
- HDF1388 cells are episomal according to the method described in US provisional application 61 / 521,153.
- the reprogramming gene was introduced using plasmid vectors pCEB-hSK-O and pCEB-hUL-G, and cultured in a maintenance culture medium (mTeSR1 (StemCell Technologies) and NutriStem (Cosmo Bio) 1: 1 mixed solution). went. The number of human iPS cell colonies was counted 30 days after the introduction of the reprogramming gene.
- pCEB-hSK-O episomal plasmid is an expression in which human SOX2 and human KLF4 translation regions are linked via a 2A sequence and human OCT3 / 4 translation regions are placed under the control of separate CAG promoters.
- a plasmid having a cassette see FIG. 10I.
- the human L-MYC and human LIN28 translation regions were joined via a 2A sequence, and the human GLISI translation region was placed under the control of separate CAG promoters. It is a plasmid having an expression cassette (see FIG. 10 (II)).
- episomal plasmids include plasmids described in Okita et al., “A more efficient method to generate integration-free human iPS cells”, Nature Methods, 8 (5), 409 (2011) and International Publication WO2011 / 016588. It was produced using.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
[1]ラミニン、または、ヘテロ3量体を形成しているラミニンフラグメントのα鎖のN末端、α鎖のC末端、β鎖のN末端およびγ鎖のN末端の少なくとも1箇所に細胞増殖制御分子が結合していることを特徴とする改変ラミニン。
[2]細胞増殖制御分子が、細胞接着分子である前記[1]に記載の改変ラミニン。
[3]細胞増殖制御分子が、増殖因子結合分子である前記[1]に記載の改変ラミニン。
[4]ラミニンフラグメントが、インテグリン結合活性を有していることを特徴とする前記[1]~[3]のいずれかに記載の改変ラミニン。
[5]ラミニンフラグメントが、ラミニンE8フラグメントである前記[4]に記載の改変ラミニン。
[6]ラミニンが、α1~α5から選択される1種のα鎖、β1~β3から選択される1種のβ鎖、γ1~γ3から選択される1種のγ鎖からなることを特徴とする前記[1]~[5]のいずれかに記載の改変ラミニン。
[7]ラミニンが、ラミニンα5β1γ1またはラミニンα3β3γ2である前記[6]に記載の改変ラミニン。
[8]細胞接着分子が、以下の(a)~(e)から選択される少なくとも1種以上であることを特徴とする前記[2]に記載の改変ヒトラミニン。
(a)インテグリンと結合する細胞接着分子
(b)膜結合型プロテオグリカンと結合する細胞接着分子
(c)ジスコイジンドメイン受容体と結合する細胞接着分子
(d)ジストログリカンと結合する細胞接着分子
(e)細胞表面の糖鎖と結合する細胞接着分子
[9]細胞接着分子が、以下の(a)~(k)から選択される少なくとも1種以上であることを特徴とする前記[2]に記載の改変ヒトラミニン。
(a)フィブロネクチンまたはその細胞接着活性部位を含むフラグメント
(b)コラーゲンまたはその細胞接着活性部位を含むフラグメント
(c)ビトロネクチンまたはその細胞接着活性部位を含むフラグメント
(d)ネフロネクチンまたはその細胞接着活性部位を含むフラグメント
(e)オステオポンティンまたはその細胞接着活性部位を含むフラグメント
(f)MAEGまたはその細胞接着活性部位を含むフラグメント
(g)テネイシンまたはその細胞接着活性部位を含むフラグメント
(h)SVEP1またはその細胞接着活性部位を含むフラグメント
(i)TGF-β1 latency associated peptideまたはその細胞接着活性部位を含むフラグメント
(j)TGF-β3 latency associated peptideまたはその細胞接着活性部位を含むフラグメント
(k)ラミニンα鎖の球状ドメイン4および/または5
ラミニンα鎖の球状ドメイン4および/または5
[10]増殖因子結合分子が、以下の(a)~(f)から選択される少なくとも1種以上であることを特徴とする前記[3]に記載の改変ヒトラミニン。
(a)パールカンまたはその増殖因子結合部位を含むフラグメント
(b)アグリンまたはその増殖因子結合部位を含むフラグメント
(c)XVIII型コラーゲンまたはその増殖因子結合部位を含むフラグメント
(d)シンデカンまたはその増殖因子結合部位を含むフラグメント
(e)グリピカンまたはその増殖因子結合部位を含むフラグメント
(f)latent TGF-βbinding proteinまたはその増殖因子結合部位を含むフラグメント
[11]ヒト由来である前記[1]~[10]のいずれかに記載の改変ラミニン。
[12]哺乳動物細胞の培養方法であって、前記[1]~[11]のいずれかに記載の改変ヒトラミニンの存在下で培養することを特徴とする培養方法。
[13]哺乳動物細胞が、ES細胞、iPS細胞または体性幹細胞である前記[12]に記載の培養方法。
[14]フィーダー細胞を用いないことを特徴とする前記[12]または[13]に記載の培養方法。
[15]前記[1]~[11]のいずれかに記載の改変ヒトラミニンがコーティングされていることを特徴とする培養基材。
[16]改変ヒトラミニンが0.03~25μg/cm2の濃度でコーティングされていることを特徴とする前記[15]に記載の培養基材。
[17]前記[1]~[11]のいずれかに記載の改変ラミニンの存在下で、核初期化物質を体細胞に接触させる工程を含むことを特徴とするiPS細胞の樹立方法。
[18]前記核初期化物質は、Octファミリー、Soxファミリー、Klfファミリー、LinファミリーおよびGlisファミリー並びにそれらをコードする核酸からなる群より選択される1種類以上の物質を含むことを特徴とする前記[17]に記載のiPS細胞の樹立方法。
本発明は、ラミニン、または、ヘテロ3量体を形成しているラミニンフラグメントのα鎖のN末端、α鎖のC末端、β鎖のN末端およびγ鎖のN末端の少なくとも1箇所に細胞増殖制御分子が結合していることを特徴とする改変ラミニンを提供する。
ラミニンは、α鎖、β鎖およびγ鎖の3本のサブユニット鎖からなるヘテロ3量体分子である。α鎖はα1~α5の5種類、β鎖はβ1~β3の3種類、γ鎖はγ1~γ3の3種類が知られており、それらの組み合わせで少なくとも12種類以上のアイソフォームが存在する(表1参照)。本発明の改変ラミニンを構成するラミニンは、いずれのアイソフォームであってもよい。すなわち、本発明の改変ラミニンを構成するラミニンは、α1~α5から選択される1種のα鎖、β1~β3から選択される1種のβ鎖、γ1~γ3から選択される1種のγ鎖からなるものであればよい。具体的には、表1に記載の12種類、およびこれら以外のすべてのアイソフォームを好適に用いることができる。好ましくはラミニンα3β3γ2、ラミニンα5β1γ1である。
(a)インテグリンと結合する細胞接着分子
(b)膜結合型プロテオグリカンと結合する細胞接着分子
(c)ジスコイジンドメイン受容体と結合する細胞接着分子
(d)ジストログリカンと結合する細胞接着分子
(e)細胞表面の糖鎖と結合する細胞接着分子
本発明は、上記本発明の改変ラミニンの存在下で哺乳動物細胞を培養する培養方法を提供する。本発明の改変ラミニンは、高い細胞接着活性および/または増殖刺激活性を有しているので、哺乳動物細胞の足場となる細胞外基質として用いることにより、従来フィーダー細胞を用いて培養している細胞を、フィーダー細胞を用いることなく培養することが可能となる。
(i) Liu, Y. et al., Biochem. Biophys. Res. Commun., 346:131-139, 2006.
(ii) Vallier, L. et al., J. Cell Sci. 118:4495-4509, 2005.
(iii) Li, Y. et al., Biotechnol. Bioeng., 91:688-698, 2005.
(iv) Yao, S. et al., Proc. Natl. Acad. Sci. U.S.A., 103:6907-6912, 2006.
(v) Lu, J. et al., Proc. Natl. Acad. Sci. U.S.A., 103:5688-5693, 2006.
(1)フィーダー細胞との共培養系からヒトiPS細胞を回収する
以下の方法1または方法2のいずれかの方法で、フィーダー細胞との共培養系からヒトiPS細胞を回収する。
方法1:
フィーダー細胞(例えばMEF)と共培養しているヒトiPS細胞の培養ディッシュ(3~5日目)に0.25%トリプシン/DMEM-F12を添加して(例えば1ml/60mmディッシュ)、37℃で2~3分間恒温処理し、培養ディッシュをDMEM-F12で洗浄してフィーダー細胞を除去する。培養液を加えて全体細胞を物理的に剥離した細胞懸濁液をBD Falconセルストレーナー100μm(BD Falcon #352460)に通した後、ストレーナーを洗浄することでヒトiPS細胞のコロニーのみを分離し、回収する。
フィーダー細胞(例えばMEF)と共培養しているヒトiPS細胞の培養ディッシュ(3~5日目)に細胞剥離液(例えば、ES/iPS細胞用剥離液(リプロセル RCHETP002)、1mg/ml dispase/DMEM-F12、10mg/ml collagenaseIV/DMEM-F12など)を添加して(例えば1ml/60mmディッシュ)、37℃で5分間恒温処理し、ヒトiPS細胞とMEFを剥離する。細胞を15ml遠心チューブに移し、培養液を約10ml入れて細胞を懸濁した後、5分間チューブを静置してコロニーのみを沈降させる。上清を除去し、同様の操作を2回以上繰り返して、ヒトiPS細胞のコロニーのみを沈降させ、回収する。
回収したヒトiPS細胞のコロニーを単一細胞に分散させる。単一細胞に分散させる方法は特に限定されないが、例えば、トリプシン処理する方法、P-1000ピペットマン等を用いて培養液を数回フラッシングすることによりコロニーを砕く方法等が挙げられる。単一細胞に分散させた後、適切な培養液(例えばTeSR2など)に懸濁し、ヒト由来の改変ラミニンをコーティング(例えば1.0μg/cm2)した培養ディッシュに播種する。培養は、用いた培養液に適合するCO2濃度条件で行い、培養液の交換は毎日行う。
拡大エリアの不足あるいはコロニー内に死細胞の出現が目立つようになるのを目安に、継代操作を行う。本発明の培養方法では、従来の方法と同様にヒトiPS細胞を適度な大きさのコロニー形態を維持した状態で播種する方法で継代培養を行ってもよく、ヒトiPS細胞を単一細胞に分散させて播種する方法で継代培養を行ってもよい。ここで、単一細胞に分散された状態は、細胞懸濁液中の全細胞が単一細胞に分散されていることを要するものではなく、単一細胞に分散された細胞以外に数個~十数個程度が接着した状態の細胞が細胞懸濁液中に含まれている状態も単一細胞に分散された状態に含まれる。
ヒトiPS細胞を培養している培養ディッシュに、TrypLE Select(商品名、Invitrogen #12563011)を添加して(例えば1ml/100mmディッシュ)、37℃で5分間恒温処理する。例えばP-1000ピペットマン等を用いて培養液を数回フラッシングすることによりヒトiPS細胞のコロニーを砕き、単一細胞に分散させる。培養液を加えて細胞を懸濁し、遠心チューブに回収する。遠心(1000×g、3分)と同培養液による洗浄操作を2度繰り返した後、新鮮な培養液に細胞を懸濁し、ヒト由来の改変ラミニンをコーティング(例えば1.0μg/cm2)した培養ディッシュに、例えば約40000細胞/cm2の播種密度で単一細胞に分散したヒトiPS細胞を播種する。培養は、用いた培養液に適合するCO2濃度条件で行い、培養液の交換は毎日行う。
ヒトiPS細胞を単一細胞に分散しない場合は、細胞の剥離にCollagenaseIV、Dispase、Accutase等の酵素を用いる。ヒトiPS細胞を培養している培養ディッシュに、10mg/ml collagenase/DMEM-F12、または2mg/ml dispase/DMEM-F12、またはAccutase(Millipore #SCR005)を添加して(例えば1ml/60mmディッシュ)、37℃で5分間恒温処理する。酵素液を除いて培養液を加え、例えばP-1000のピペットマン等を用いて培養液を数回フラッシングすることによりヒトiPS細胞が約50~約100個のコロニー状を維持する程度に小さく砕く。細胞懸濁液を遠心チューブに回収し、遠心(200×g、3分)と同培養液による洗浄操作を2度繰り返した後、新鮮な培養液に細胞を懸濁し、ヒト由来の改変ラミニンをコーティング(例えば1.5μg/cm2)した培養ディッシュに2分の1~4分の1希釈量を播種する。培養は、用いた培養液に適合するCO2濃度条件で行い、培養液の交換は毎日行う。
本発明は、上記本発明の改変ラミニンの存在下でiPS細胞を樹立する方法を提供する。本発明のiPS細胞樹立方法は、上記本発明の改変ラミニンの存在下で核初期化物質を体細胞に接触させる工程を含むものであればよい。さらに核初期化物質の接触を受けた体細胞を、本発明の改変ラミニンの存在下で培養する工程を含むことが好ましい。
(vi) Takahashi, K. and Yamanaka, S., Cell, 126: 663-676 (2006)
(vii) Okita, K. et al., Nature, 448: 313-317 (2007)
(viii) Wernig, M. et al., Nature, 448: 318-324 (2007)
(ix) Maherali, N. et al., Cell Stem Cell, 1: 55-70 (2007)
(x) Nakagawa, M. et al., Nat. Biotethnol., 26: 101-106 (2008)
(xi) Takahashi, K. et al., Cell, 131: 861-872 (2007)
(xii) Yu, J. et al., Science, 318: 1917-1920 (2007)
(xiii) Maekawa, M. et al., Nature, 474: 225-229 (2011)
このように、体細胞に特定因子を導入することにより、ヒトおよびマウスで、分化多能性においてES細胞と遜色のないiPS細胞を作製できることが示された。当該特定因子については、本発明において「核初期化物質」と定義を行うものとし、体細胞に導入することにより、あるいはiPS細胞の樹立効率改善因子と共に体細胞に接触させることにより、該体細胞からiPS細胞を誘導することができる物質(群)であれば、タンパク性因子またはそれをコードする核酸(ベクターに組み込まれた形態を含む)、あるいは低分子化合物等のいかなる物質から構成されてもよい。
(1) Oct3/4, Klf4, c-Myc
(2) Oct3/4, Klf4, c-Myc, Sox2(ここで、Sox2はSox1, Sox3, Sox15, Sox17またはSox18で置換可能である。また、Klf4はKlf1, Klf2またはKlf5で置換可能である。さらに、c-MycはT85A(活性型変異体), L-Mycで置換可能である。)
(3) Oct3/4, Klf4, c-Myc, Sox2, Fbx15, Nanog, ERas, TcelI
(4) Oct3/4, Klf4, c-Myc, Sox2, TERT, SV40 Large T antigen(以下、SV40LT)
(5) Oct3/4, Klf4, c-Myc, Sox2, TERT, HPV16 E6
(6) Oct3/4, Klf4, c-Myc, Sox2, TERT, HPV16 E7
(7) Oct3/4, Klf4, c-Myc, Sox2, TERT, HPV6 E6, HPV16 E7
(8) Oct3/4, Klf4, c-Myc, Sox2, TERT, Bmil
(以上、WO 2007/069666を参照(但し、上記(2)の組み合わせにおいて、Sox2からSox18への置換、Klf4からKlf1もしくはKlf5への置換については、Nature Biotechnology, 26, 101-106 (2008)を参照)。「Oct3/4, Klf4, c-Myc, Sox2」の組み合わせについては、Cell, 126, 663-676 (2006)、Cell, 131, 861-872 (2007) 等も参照。「Oct3/4, Klf4(またはKlf5),c-Myc, Sox2」の組み合わせについては、Nat. Cell Biol., 11, 197-203 (2009) も参照。「Oct3/4, Klf4, c-Myc, Sox2, hTERT, SV40LT」の組み合わせについては、Nature, 451, 141-146 (2008)も参照。)
(9) Oct3/4, Klf4, Sox2(Nature Biotechnology, 26, 101-106 (2008)を参照)
(10) Oct3/4, Sox2, Nanog, Lin28(Science, 318, 1917-1920 (2007)を参照)
(11) Oct3/4, Sox2, Nanog, Lin28, hTERT, SV40LT(Stem Cells, 26, 1998-2005 (2008)を参照)
(12) Oct3/4, Klf4, c-Myc, Sox2, Nanog, Lin28(Cell Research (2008) 600-603を参照)
(13) Oct3/4, Klf4, c-Myc, Sox2, SV40LT(Stem Cells, 26, 1998-2005 (2008)も参照)
(14) Oct3/4, Klf4(Nature 454:646-650 (2008)、Cell Stem Cell, 2:525-528(2008))を参照)
(15) Oct3/4, c-Myc(Nature 454:646-650 (2008)を参照)
(16) Oct3/4, Sox2(Nature, 451, 141-146 (2008), WO2008/118820を参照)
(17) Oct3/4, Sox2, Nanog(WO2008/118820を参照)
(18) Oct3/4, Sox2, Lin28(WO2008/118820を参照)
(19) Oct3/4, Sox2, c-Myc, Esrrb(ここで、EsrrbはEsrrgで置換可能である。Nat. Cell Biol., 11, 197-203 (2009) を参照)
(20) Oct3/4, Sox2, Esrrb(Nat. Cell Biol., 11, 197-203 (2009) を参照)
(21) Oct3/4, Klf4, L-Myc(Proc. Natl. Acad. Sci. USA., 107, 14152-14157 (2010) を参照)
(22) Oct3/4, Nanog
(23) Oct3/4(Cell 136: 411-419 (2009)、Nature, 08436, doi:10.1038 published online(2009)
(24) Oct3/4, Klf4, c-Myc, Sox2, Nanog, Lin28, SV40LT(Science, 324: 797-801 (2009)を参照)
(25) Oct3/4, Klf4, Sox2, c-Myc, Glis1(Nature, 474: 225-229 (2011), WO2010/098419, WO2011/102531を参照)
(26) Oct3/4, Klf4, Sox2, Glis1(Nature, 474: 225-229 (2011) , WO2010/098419, WO2011/102531を参照)
上記(1)~(26)において、Oct3/4に代えて他のOctファミリーのメンバー、例えばOct1A、Oct6などを用いることもできる。また、Sox2(またはSox1、Sox3、Sox15、Sox17、Sox18)に代えて他のSoxファミリーのメンバー、例えばSox7などを用いることもできる。また、Glis1に代えて他のGlisファミリーメンバーGlis2、Glis3などを用いることもできる。さらに上記(1)~(26)においてc-MycまたはLin28を核初期化物質として含む場合、c-MycまたはLin28に代えてそれぞれL-MycまたはLin28Bを用いることもできる。
これらの組み合わせの中で、Oct3/4, Sox2, Klf4, L-Myc, Lin28およびGlis1から選択される少なくとも1つ、好ましくは2つ以上、より好ましくは3つ以上が、好ましい核初期化物質の例として挙げられる。
本発明は、幹細胞の急速拡大方法を提供する。本発明の急速拡大方法は、幹細胞を単一細胞に分散する工程と、単一細胞に分散された幹細胞を、上記本発明の改変ラミニンの存在下で培養する工程とを含み、単一細胞に分散された幹細胞を約2×104~約20×104cell/cm2の密度で播種するものであればよい。播種密度は、約3×104~約10×104cell/cm2がより好ましく、約4×104~約5×104cell/cm2がさらに好ましい。従来の培養系では、単一に分散された幹細胞を上記細胞密度で播種した場合の接着効率は非常に低いものであるが、本発明の急速拡大方法によれば、顕著に高い接着効率が得られ、その後旺盛に増殖するので、従来法と比較して格段の速度で幹細胞を増殖させることができる。
本発明の幹細胞の急速拡大方法は、ES細胞やiPS細胞などの多能性幹細胞に適用することが好ましく、ES細胞に適用することがより好ましい。また、ヒト多能性幹細胞に適用することが好ましく、ヒトES細胞に適用することがより好ましい。本発明の幹細胞の急速拡大方法をヒト幹細胞に適用する場合には、ヒト由来の改変ラミニンを使用することが好ましい。
本発明は、幹細胞の単一細胞由来クローン分離方法を提供する。本発明の単一細胞由来クローン分離方法は、幹細胞を単一細胞に分散する工程と、単一細胞に分散された幹細胞を、上記本発明の改変ラミニンの存在下で培養する工程とを含み、単一細胞由来のコロニーを形成させるものであればよい。本発明の単一細胞由来クローン分離方法によれば、従来の培養系では困難であった幹細胞の単一細胞由来クローンを形成させ、分離することができ、均一な幹細胞を容易に取得することが可能となる。
本発明の幹細胞の単一細胞由来クローン分離方法は、ES細胞やiPS細胞などの多能性幹細胞に適用することが好ましく、ES細胞に適用することがより好ましい。また、ヒト多能性幹細胞に適用することが好ましく、ヒトES細胞に適用することがより好ましい。本発明の幹細胞の単一細胞由来クローン分離方法をヒト幹細胞に適用する場合には、ヒト由来の改変ラミニンを使用することが好ましい。
本発明は、幹細胞の単一細胞培養方法を提供する。本発明の単一細胞培養方法は、幹細胞を単一細胞に分散する工程と、単一細胞に分散された幹細胞を、上記本発明の改変ラミニンの存在下で培養する工程とを含み、細胞を増殖させることなく単一細胞の状態で維持するものであればよい。コロニーを形成した幹細胞は、コロニー周辺部とコロニー内部とで細胞の状態が異なる場合があるが、本発明の単一細胞培養方法によれば、細胞はコロニーを形成しないので、状態の均一な幹細胞を得ることができ、分化誘導効率の向上が期待できる。
本発明の幹細胞の単一細胞培養方法は、ES細胞やiPS細胞などの多能性幹細胞に適用することが好ましく、ES細胞に適用することがより好ましい。また、ヒト多能性幹細胞に適用することが好ましく、ヒトES細胞に適用することがより好ましい。本発明の幹細胞の単一細胞培養方法をヒト幹細胞に適用する場合には、ヒト由来の改変ラミニンを使用することが好ましい。
本発明は、上記本発明の改変ラミニンがコーティングされている培養基材を提供する。本発明の培養基材を用いて培養する細胞は特に限定されず、培養可能な哺乳動物細胞であればどのような細胞でも本発明の培養基材を用いて培養することができる。好ましくは幹細胞である。幹細胞には体性幹細胞、多能性幹細胞などが含まれる。体性幹細胞としては、神経幹細胞、間葉系幹細胞、造血幹細胞などが挙げられる。多能性幹細胞としては、ES細胞(胚性幹細胞)、iPS細胞(人工多能性幹細胞)、mGS細胞(多能性生殖幹細胞)、ES細胞と体細胞との融合細胞などが挙げられる。より好ましくは多能性幹細胞であり、さらに好ましくはES細胞、iPS細胞である。哺乳動物としては、ヒト、マウス、ラット、ウシ、ブタ等が挙げられる。なかでもヒトが好ましい。本発明の培養基材は、従来フィーダー細胞を用いて培養している細胞を、フィーダー細胞を用いることなく培養する場合に非常に有用である。
(1)Plus#1ラミニンE8用発現ベクターの作製
Plus#1ラミニンE8(組換えヒトラミニンα5β1γ1のE8フラグメントとヒトラミニンα1鎖球状ドメイン4-5番目を融合させた改変ヒトラミニン)は、組換えヒトラミニン511E8(以下「rhLM511E8」と記す)を作製した後に、ヒトラミニンα5鎖のE8のC末端部にヒトラミニンα1鎖球状ドメイン4-5番目(以下「ヒトラミニンα1鎖LG45」と記す)を付加して作製した。
rhLM511E8は、Idoら(Hiroyuki Ido, Aya Nakamura, Reiko Kobayashi, Shunsuke Ito, Shaoliang Li, Sugiko Futaki, and Kiyotoshi Sekiguchi, “The requirement of the glutamic acid residue at the third position from the carboxyl termini of the laminin γ chains in integrin binding by laminins”, The Journal of Biological Chemistry, 282, 11144-11154, 2007)に記載の方法に従い、以下のように作製した。
(i) 6×Hisタグ導入用プライマー
5’-ATGATGATGAAGCTTATCGATACCGT-3’(forward、配列番号1)
5’-CATCATCATGATATCGAATTCCTGCA-3’(reverse、配列番号2)
(ii) HAタグ導入用プライマー
5’-ATCATATGGATAAAGCTTATCGATACCGT-3’(forward、配列番号3)
5’-GTGCCAGATTATGCAGATATCGAATTCCT-3’(reverse、配列番号4)
(iii) FLAGタグ導入用プライマー
5’-ATCCTTGTAATCAAGCTTATCGATACCGT-3’(forward、配列番号5)
5’-GATGATGATAAGGATATCGAATTCCT-3’(reverse、配列番号6)
(iv) α5鎖E8フラグメント増幅用プライマー
5’-GCTGCCGAGGATGCTGCTGGCCAGG-3’(forward、配列番号7)
5’-CTAGGCAGGATGCCGGGCGGGCTGA-3’(reverse、配列番号8)
(v) β1鎖E8フラグメント増幅用プライマー
5’-CTTCAGCATAGTGCTGCTGACATTG-3’(forward、配列番号9)
5’-TTACAAGCATGTGCTATACACAGCAAC-3’(reverse、配列番号10)
(vi) γ1鎖E8フラグメント増幅用プライマー
5’-AATGACATTCTCAACAACCTGAAAG-3’(forward、配列番号11)
5’-CTAGGGCTTTTCAATGGACGGGGTG-3’(reverse、配列番号12)
5’側から、マウスIg-κ鎖V-J2-Cシグナルペプチド-6×Hisタグ-ヒトラミニンα5鎖E8-ヒトラミニンα1鎖LG45を順にコードするDNA断片を獲得するために、ヒトラミニンα5鎖E8をコードするDNA断片と、ヒトラミニンα1鎖LG45をコードするDNA断片をそれぞれ取得し、エクステンションPCRによってこれら2種類のDNA断片を連結・増幅した。増幅産物を制限酵素AscIで消化し、ヒトラミニンα5鎖E8発現ベクターのAscI-PmeI部位に挿入し、ヒトラミニンα1鎖LG45融合ヒトラミニンα5鎖E8フラグメント発現ベクターを作製した。
(vii) ヒトラミニンα5鎖部分断片増幅用プライマー
5’-CAATGATCTGGAGCTGGCCGACGCCTACTACCTG-3’(forward、配列番号13)
5’-CTCTGCATCAGGCCCCAGGCCCGGGGTC-3’(reverse、配列番号14)
(viii) ヒトラミニンα1鎖LG45部位増幅用プライマー
5’-CCTGGGGCCTGATGCAGAGGACAGCAA-3’(forward、配列番号15)
5’-AAACTCAGGACTCGGTCCCAGGACAGGAATGAAGG-3’(reverse、配列番号16)
(ix) ヒトラミニンα5鎖E8のC末端部とヒトラミニンα1鎖LG45部位増幅用プライマー
5’-CAATGATCTGGAGCTGGCCGACGCCTACTACCTG-3’(forward、配列番号13)
5’-AAACTCAGGACTCGGTCCCAGGACAGGAATGAAGG-3’(reverse、配列番号16)
Plus#2ラミニンE8(rhLM511E8とヒトフィブロネクチンIII型モジュールの7番目~10番目を融合させた改変ヒトラミニン)はrhLM511E8を作製した後に、ヒトラミニンγ1鎖のE8のN末端部にヒトフィブロネクチンの細胞接着部位(ヒトフィブロネクチンIII型モジュールの7番目~10番目、以下「FNIII7~10」と記す)を付加して作製した。
上記(1-1)と同様の方法でヒトラミニンα5鎖E8フラグメント(N末端側に6×Hisタグを含む)、β1鎖E8フラグメント(N末端側にHAタグを含む)、γ1鎖E8フラグメント(N末端側にFLAGタグを含む)の発現ベクターをそれぞれ作製した。
5’側から、マウスIg-κ鎖V-J2-Cシグナルペプチド-FLAGタグ-FNIII7~10-γ1鎖E8を順にコードするDNA断片を獲得するために、マウスIg-κ鎖V-J2-Cシグナルペプチド-FLAGタグをコードするDNA断片、FNIII7~10をコードするDNA断片、およびγ1鎖E8フラグメントをコードするDNA断片をそれぞれ取得し、エクステンションPCRによってこれら3種類のDNA断片を連結・増幅した。増幅産物を制限酵素NheIとNotIで消化し、哺乳細胞用発現ベクターpSecTag2B(Invitrogen、マウスIg-κ鎖V-J2-Cシグナルペプチドをコードする遺伝子配列を内在的に有する。)の当該部位に挿入し、FNIII7-10融合ヒトラミニンγ1E8フラグメント発現ベクターの発現ベクターを作製した。
(x) シグナルペプチド配列-FLAGタグ配列増幅用プライマー
5’-GAGGTCTATATAAGCAGAGCTCTCTGGCTAACTA-3’(forward、配列番号17)
5’-TGGTGGAGACAATGGATCCTTATCATCATCATCC-3’(reverse、配列番号18)
(xi) γ1鎖E8フラグメント配列増幅用プライマー
5’-TAATTACCGAACAGATAATGACATTCTCAACAACC-3’(forward、配列番号19)
5’-GAAAGGACAGTGGGAGTGGCACC-3’(reverse、配列番号20)
(xii) FNIII7~10配列増幅用プライマー
5’-GATGATGATAAGGATCCATTGTCTCCACCAACAA-3’(forward、配列番号21)
5’-ATGTCATTATCTGTTCGGTAATTAATGGAAATTGG-3’(reverse、配列番号22)
(xiii) FNIII7~10融合ヒトラミニンγ1E8フラグメント増幅用プライマー
5’-GAGGTCTATATAAGCAGAGCTCTCTGGCTAACTA-3’(forward、配列番号17)
5’-GAAAGGACAGTGGGAGTGGCACC-3’(reverse、配列番号20)
Plus#1ラミニンE8とPlus#2ラミニンE8の発現は、作製した各鎖の発現ベクターをFreeStyle293-F細胞(商品名、Invitrogen、以下「293-F細胞」と記す)に導入して行った。すなわち、Plus#1ラミニンE8の場合は、ヒトラミニンα1鎖LG45融合ヒトラミニンα5鎖E8フラグメント発現ベクター、ヒトβ1鎖E8フラグメント発現ベクターおよびヒトγ1鎖E8フラグメント発現ベクターを293-F細胞に導入し、Plus#2ラミニンE8の場合は、ヒトα5鎖E8フラグメント発現ベクター、ヒトβ1鎖E8フラグメント発現ベクターおよびFNIII7~10融合ヒトラミニンγ1E8フラグメント発現ベクターを293-F細胞に導入した。300mlの293-F細胞(1.0×106個/ml)にトランスフェクション試薬293fectin(商品名、Invitrogen)およびOpti-MEM(商品名、Invitrogen)を用いて各鎖発現ベクターを150μgずつ同時にトランスフェクトし、72時間培養を行った後、培養液を回収した。培養液は1000×gで10分間遠心し、その上清をさらに15,000×gで30分間遠心し、細胞や不溶物を除去した。培養上清に10mlのNi-NTA agarose(キアゲン)を添加し一晩インキュベートして目的タンパク質を吸着させた。Ni-NTA agaroseを回収し、TBS(-)(Ca、Mgを含まないトリス緩衝生理的食塩水)および10mMイミダゾール/TBS(-)で洗浄したのち200mMイミダゾール/TBS(-)で溶出した。A280の吸光度により溶出画分中におけるタンパク質量を確認し、目的タンパク質が溶出された画分に3mlのANTI-FLAG M2 affinity Gel(シグマ)を添加し、4℃で一晩旋回させた。ゲルをポリプレップカラム(Bio-Rad、#731-1550B04)に移し、TBS(-)で洗浄後、100μg/ml FLAG peptide(Sigma、#F3290)を含むTBS(-)で溶出した。溶出フラクションを銀染色で確認し、溶出された画分を合わせてPBS(-)(リン酸緩衝生理的食塩水)に対して透析を行った。透析後の精製物を0.22μmのディスクシリンジフィルター(Millipore、#SLGV033RS)に通すことで滅菌し、-80℃で保存した。
SDS-PAGE法により精製したPlus#1ラミニンE8とPlus#2ラミニンE8の電気泳動パターンをrhLM511E8と比較した。5%~20%の濃度勾配をもつポリアクリルアミドゲル(ATTO、#2331830)の1ウェルにrhLM511E8を1.5μg、Plus#1ラミニンE8を1.9μg、Plus#2ラミニンE8を1.9μgそれぞれアプライし、20mAで75分間電気泳動した。電気泳動は、Laemmli法に従い、25mMトリス、192mMグリシン、0.1%ドデシル硫酸ナトリウムからなる緩衝液を用いて還元条件下で行った。タンパク質の染色にはQuick-CBB(WAKO、#299-50101)を用いた。
結果を図1に示した。Plus#1ラミニンE8では3本のバンド(高分子側からα5E8+α1LG45、γ1E8、β1E8)が観察された。α5E8+α1LG45のバンド位置はα5E8より高分子側にシフトしていた。この結果は、α5E8にα1LG45が付加されていることを示している。Plus#2ラミニンE8でも3本のバンド(高分子側からα5E8、γ1E8+FNIII7~10、β1E8)が観察された。γ1E8+FNIII7~10のバンド位置はγ1E8より高分子側にシフトしていた。この結果は、γ1E8にFNIII7~10が付加されていることに示している。以上の結果から、設計したPlus#1ラミニンE8およびPlus#2ラミニンE8が得られていることを確認した。
(1)ヒトiPS細胞
ヒトiPS細胞は独立行政法人医薬基盤研究所生物資源バンクより購入した株(クローン名:tic(JCRB1331))を使用した。tic細胞は、独立行政法人医薬基盤研究所生物資源バンクが推奨する方法に従い、マウスフィーダー細胞との共培養で維持した。共培養ディッシュに、1U/mlディスパーゼ/DMEM-F12を添加し、tic細胞のコロニーをスクレーパーでかき集めた。このtic細胞コロニーとマウスフィーダー細胞を含む溶液をBD Falconセルストレーナー100μmに通し、ストレーナーを洗浄することでtic細胞コロニーを分離した。残留したコロニーをゼノフリー培地であるTeSR2(商品名、STEMCELL TECHNOLOGIES)で回収し、P-1000ピペットマンで細かく砕いた後、TeSR2に再懸濁し、マトリゲルをコートした培養器に播種した。37℃、5%CO2条件下、毎日培養液交換を行い、4-5日まで拡大培養を行った。このように拡大培養された細胞を実験に供した。
細胞外基質として、Plus#1ラミニンE8、Plus#2ラミニンE8およびBDマトリゲルヒトES細胞用(商品名、BD Bioscience #354277、以下「マトリゲル」と記す)を使用した。Plus#1ラミニンE8溶液、Plus#2ラミニンE8溶液、マトリゲル溶液をリン酸緩衝生理的食塩水(Invitrogen、#10010-023)で希釈した後、BD FALCON MICROTEST96ウェルマイクロプレート(商品名、BD Biosciences、#353072)に添加し、4℃で一晩静置してコーティングを行った。なお、マトリゲル溶液は0.1~30μg/cm2、Plus#1ラミニンE8溶液およびPlus#2ラミニンE8溶液は0.0038~3.8μg/cm2の範囲になるようにプレートへ添加した。
TeSR2を用いて培養したヒトiPS細胞(tic)から培地を除去した後、4.8mM EDTAを含むリン酸緩衝生理的食塩水を加えて、3分間37℃で恒温処理した。次に、TrypLE Select(商品名、Invitrogen、#12563-011)を加えて3分間、37℃で恒温処理し、細胞を単一細胞に分散させた。細胞数をカウントした後、プレートに2.7×104cell/well(8.2×104cell/cm2)の密度で細胞を播種した。細胞播種から6時間後、上清を除いてDMEM-F12で1度ウェルを洗浄し、10%中性ホルマリンを含むリン酸緩衝生理的食塩水を加えて10分間細胞を固定した。細胞の染色には、ディフ・クイック(登録商標、シスメックス株式会社、#16920)を用いた。風乾の後、1%SDSを加えて細胞を可溶化し、マルチプレートリーダーを用いて波長595nmの吸光度を測定した。
結果を図2に示した。Plus#1ラミニンE8とPlus#2ラミニンE8は低濃度のコーティング(0.13μg/cm2)でも顕著に高い接着細胞数を示した。一方、汎用されているマトリゲルは10μg/cm2のコーティングで接着細胞数が最大値に達した。しかし、この最大値はPlus#1ラミニンE8およびPlus#2ラミニンE8の最大値より低かった。この結果から、Plus#1ラミニンE8およびPlus#2ラミニンE8は、マトリゲルの約1/80のタンパク質量でマトリゲルより高いヒトiPS細胞の細胞接着活性を示すことが明らかとなった。加えて、Plus#1ラミニンE8とPlus#2ラミニンE8の至適コーティング濃度は約0.13~3.8μg/cm2と考えられた。
(1)ヒトiPS細胞
ヒトiPS細胞は32R1(Masato Nakagawa, Nanako Takizawa, Megumi Narita, Tomoko Ichisaka, Shinya Yamanaka, “Promotion of direct reprogramming by transformation-deficient Myc.”, Proceedings of the National Academy of Sciences, 107(32), 14152-14157, 2010)を使用した。32R1細胞は、MSTOマウスフィーダー細胞上で維持した(Kazutoshi Takahashi, Koji Tanabe, Mari Ohnuki, Megumi Narita, Tomoko Ichisaka, Kiichiro Tomoda, Shinya Yamanaka, “Induction of pluripotent stem cells from adult human fibroblasts by defined factors.”, Cell,131(5), 861-872, 2007)。
細胞外基質として、Plus#1ラミニンE8、Plus#2ラミニンE8およびマトリゲルを用いた。Plus#1ラミニンE8溶液とPlus#2ラミニンE8溶液をリン酸緩衝生理的食塩水で希釈した後、6ウェルマイクロプレートに0.5μg/cm2の濃度で添加し、4℃で一晩静置、または37℃で1時間静置してコーティングを行った。マトリゲル溶液はDMEM/F12溶液で希釈した後、6ウェルマイクロプレートに35μg/cm2の濃度で添加し、室温で1時間静置してコーティングを行った。
フィーダー細胞上で培養した32R1細胞をリン酸緩衝生理的食塩水で洗浄し、細胞剥離剤(CTK溶液)を加え37℃で2分間程度処理しフィーダー細胞を除去した。その後、セルスクレーパーにて32R1細胞を回収し、細胞外基質をコーティングしたウェルに32R1細胞を播種した。24時間ごとに培地を交換した。5日目に細胞の状態を観察して写真撮影した(1st Passage)。7日目および14日目に細胞を継代し、21日目に細胞の状態を観察して写真撮影した(3rd Passage)。
ヒトiPS細胞(32R1細胞)の観察結果を図3に示した。上段の1st Passageは、各種細胞外基質をコーティングした培養器で培養を開始してから5日目の細胞の状態を示す写真であり、中段および下段の3rd Passageは、2回継代した後(各種細胞外基質をコーティングした培養器で培養を開始してから21日目)の細胞の状態を示す写真である。1st Passage(5日目)では、マトリゲルコーティング上ではほとんど細胞が残っていなかったのに対して、Plus#1ラミニンE8コーティング上、およびPlus#2ラミニンE8コーティング上では、ヒトiPS細胞が生着していた。3rd Passage(21日目)では、ヒトiPS細胞のコロニーを観察することができ、Plus#1ラミニンE8コーティング上、およびPlus#2ラミニンE8コーティング上でヒトiPS細胞を継続して培養できることが明らかとなった。Plus#1ラミニンE8とPlus#2ラミニンE8を比較すると、Plus#2ラミニンE8コーティング上のほうが、Plus#1ラミニンE8コーティング上より細胞の数が多いことが確認された。
(1)実験方法
Plus#2ラミニンE8、rhLM511E8またはフィブロネクチンと、組換えヒトα5β1インテグリンまたはα6β1インテグリンとの結合活性を測定した。フィブロネクチンは、Sekiguchiらの方法(Kiyotoshi Sekiguchi and Sen-itiroh Hakomori, “Domain structure of human plasma fibronectin. Differences and similarities between human and hamster fibronectins.”, The Journal of Biological Chemistry, 258, 3967-3973, 1983)に従い、ゼラチン不溶化アフィニティーカラムを用いて精製したものを使用した。組換えヒトα5β1インテグリンはTakagiらが作製した発現ベクターを用いて作製した(Junichi Takagi, Harold P. Erickson, and Timothy A. Springer, “C-terminal opening mimics 'inside-out' activation of integrin alpha5beta1.”, Nature structural & molecular biology, 8(5), 412-416, 2001)。この組換えヒトα5β1インテグリンはα5サブユニットとβ1サブユニットの細胞外ドメインから構成されている。また、両サブユニットを2量体化するために、α5のC末端部には主に酸性アミノ酸残基と疎水性アミノ酸残基からなる配列が、また、β1のC末端部には主に塩基性アミノ酸残基と疎水性アミノ酸残基からなる配列がそれぞれ付加されている。さらに、α5のC末端部にはFLAGタグ、β1のC末端部には6×Hisタグが付加されている。組換えヒトインテグリンα6β1はIdoらの方法(Hiroyuki Ido, Kenji Harada, Yoshiko Yagi, Kiyotoshi Sekiguchi, “Probing the integrin-binding site within the globular domain of laminin-511 with the function-blocking monoclonal antibody 4C7.”, Matrix Biology, 25(2), 112-117, 2006)に従い作製した。分子構造は上記組換えヒトα5β1インテグリンと同様である。
結果を図4に示した。Plus#2ラミニンE8はヒトフィブロネクチンと同程度の組換えヒトα5β1インテグリンに対する結合活性を示した。また、rhLM511E8は組換えヒトα5β1インテグリンに対する結合活性を示さなかった。一方、Plus#2ラミニンE8はrhLM511E8と同程度の組換えヒトα6β1インテグリンに対する結合活性を示した。また、ヒトフィブロネクチンはヒトα6β1インテグリンに対する結合活性を示さなかった。以上の結果から、Plus#2ラミニンE8はα5β1インテグリンとα6β1インテグリンに対する結合活性を有する組換えタンパク質であることが示された。
(1)ヒトES細胞
ヒトES細胞はNational Stem Cell Bankより購入したH9株を使用した。フィーダー細胞には、マイトマイシンCで処理し細胞分裂を止めたSNL細胞(McMahon, A. P. & Bradley, A. Cell 62, 1073-1085 (1990))を用い、H9細胞のフィーダー細胞上への播き直しを行った。培地には霊長類ES細胞培養用培地(ReproCELL)を用い、共培養を行った。
細胞外基質として、(全長ラミニン511は、Idoら(Hiroyuki Ido, Kenji Harada, Sugiko Futaki, Yoshitaka Hayashi, Ryoko Nishiuchi, Yuko Natsuka, Shaoliang Li, Yoshinao Wada, Ariana C. Combs, James M. Ervasti, and Kiyotoshi Sekiguchi, “Molecular dissection of the α-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10” Jhe Journal of Biological Chemistry, 279, 10946-10954, 2004.)に記載の方法に従って作製した。
H9細胞は以下の方法により、SNLフィーダー細胞との共培養系から回収した。
(3-1)培地の準備
必要量の維持培養培地(mTeSR1(StemCell Technologies社)とNutriStem(コスモバイオ社)の1:1混合溶液)に1/1000量の10mM Y-27632を加えた。
(3-2)プレートのコーティング
6ウェルマイクロプレートにPBS(-)を1.5ml/wellを入れ、Plus#1ラミニンE8(コート量:0.5μg/cm2)を4.8μg/well加え、37℃ CO2 5%インキュベーターで60分反応させた後、維持培養培地1ml/well加え培地をなじませた後、上澄みを除去した。同様に、Plus#2ラミニンE8をコーティングしたウェルマイクロプレートを準備した。全長ラミニン511も同様にコーティングした(コート量:2.0μg/cm2)。それぞれのコーティングプレートは、維持培養培地(Y-27632入り)を1.5ml/well加え、インキュベーター下で保管した。なお、マトリゲル溶液については上記条件下で、0.1~30μg/cm2の範囲になるようにプレートへ添加した。
培地を除去し、PBS4mlで一回洗浄した後に、PBSを完全に吸引除去し、CTK液を0.5ml加え、37℃でインキュベートした。殆どのフィーダー細胞が剥がれたらCTK液を吸引し、4mlのPBSで1回洗浄、その後にX0.5 TrypLE Select(Invitrogen社より購入)を600μl/wellずつ加えてなじませ、37℃ CO2 5%インキュベーターで1分さらに3分反応させた。その後、インキュベーターから取り出し顕微鏡で細胞の様子を観察し、細胞間接着が破壊され細胞が丸くなっている様子を確認した。先に加えたX0.5 TrypLE Selectを除去し、維持培養培地を3ml/well加えた後にセルスクレーパーで細胞を剥がした。
(3-4)細胞の培養
フィーダー細胞を除去し、単一に分散したH9細胞13,000個を上記にて予め調製したコーティングプレート(6-well plate)に播種し、37℃ CO2 5%インキュベーターで単一分散培養を行った。翌日、維持培養用培地に交換した。培地交換は1日おきに行い、培養開始後6、7日頃から毎日行った。
各種細胞外基質をコーティングした培養器でH9細胞の単一分散培養を行い、7日間培養を行った後、増殖した細胞コロニーをアルカリフォスファターゼ(ALP)染色した結果を図5に示した。図5中、上段左からコートなし(図中、None)、マトリゲルコート(図中、Matrigel)、全長ラミニン511コート(図中、LN511FL)、下段左からPlus#1ラミニンE8コート(図中、LN511E8plus#1)、Plus#2ラミニンE8コート(図中、LN511E8plus#2)である。アルカリフォスファターゼ染色により、下段のPlus#1ラミニンE8コートおよびPlus#2ラミニンE8コートの培養器においてH9細胞の良好な増殖が観察された。一方、上段のコートなしおよびマトリゲルコートの培養器ではH9細胞はほとんど観察されなかった。以上の結果から、Plus#1ラミニンE8またはPlus#2ラミニンE8をコーティングした培養基材を用いれば、単一分散によるヒトES細胞の培養方法を容易に提供できることが示された。
(1)ヒトiPS細胞
ヒトiPS細胞には、成人皮膚由来線維芽細胞(aHDF-Slc7al)に対してOct3/4、KLF4、SOX2、およびL-MYCの4遺伝子をレトロウイルスを用いて導入することにより樹立された32R1細胞(Masato Nakagawa, Nanako Takizawa, Megumi Narita, Tomoko Ichisaka, Shinya Yamanaka, “Promotion of direct reprogramming by transformation-deficient Myc.”, Proceedings of the National Academy of Sciences, 107(32), 14152-14157, 2010)を使用した。
Plus#1ラミニンE8、Plus#2ラミニンE8、Plus#3ラミニンE8(rhLM511E8とヒトパールカンのドメインI~IIIを融合させた改変ラミニン)、rhLM511E8およびマトリゲルを使用した。Plus#3ラミニンE8は、rhLM511E8を作製した後に、ヒトラミニンβ1鎖のE8のN末端部にヒトパールカンのドメインI~III(以下「Pln-D1/2/3」と記す)を付加して、以下のとおり作製した。
上記(1-1)と同様の方法でヒトラミニンα5鎖E8フラグメント(N末端側に6×Hisタグを含む)、β1鎖E8フラグメント(N末端側にHAタグを含む)、γ1鎖E8フラグメント(N末端側にFLAGタグを含む)の発現ベクターをそれぞれ作製した。
5’側から、マウスIg-κ鎖V-J2-Cシグナルペプチド-Pln-D1/2/3-HAタグ-β1鎖E8を順にコードするDNA断片を獲得するために、Pln-D1/2/3をコードするDNA断片を取得し、制限酵素HindIIIで消化した。消化産物をヒトラミニンβ1鎖E8フラグメント発現ベクターの当該部位に挿入し、Pln-D1/2/3融合ヒトラミニンβ1鎖E8フラグメント発現ベクターを作製した。
まず、ヒトパールカン発現ベクター(Shaoliang Li, Chisei Shimono, Naoko Norioka, Itsuko Nakano, Tetsuo Okubo, Yoshiko Yagi, Maria Hayashi, Yuya Sato, Hitomi Fujisaki, Shunji Hattori, Nobuo Sugiura, Koji Kimata and Kiyotoshi Sekiguchi, “Activin A Binds to Perlecan through Its Pro-region That Has Heparin/Heparan Sulfate Binding Activity”, Journal of Biological Chemistry, 285(47), 36645-36655, 2010)を鋳型として、以下のプライマーを用いてPCRを行い、Pln-D1/2/3に相当する領域(Gly25-Glu1680)を増幅した。なお、プライマーの5’側には制限酵素HindIII認識配列が付加されている。得られたDNA断片を、制限酵素HindIIIで消化し、ヒトラミニンβ1鎖E8フラグメント発現ベクターの当該部位に挿入し、Pln-D1/2/3融合ヒトラミニンβ1鎖E8フラグメント発現ベクターを作製した。
(xiv) Pln-D1/2/3配列増幅用プライマー
5’-ACGAAGCTTGGGCTGAGGGCATACGATGGC-3’(forward、配列番号23)
5’-ATAAAGCTTCTCGACCACCAGTGGGGCTTGG-3’(reverse、配列番号24)
実施例1の(3)と同様の方法で、Plus#3ラミニンE8の発現および精製を行った。すなわち、ヒトα5鎖E8フラグメント発現ベクター、Pln-D1/2/3融合ヒトラミニンβ1鎖E8フラグメント発現ベクターおよびヒトγ1鎖E8フラグメント発現ベクターを293-F細胞に導入した以外は、実施例1の(3)と同様に行った。
32R1細胞は以下の方法により、SNLフィーダー細胞との共培養系から回収した。
(3-1)培地の準備
必要量の維持培養培地(mTeSR1(StemCell Technologies社)とNutriStem(コスモバイオ社)の1:1混合溶液)に1/1000量の10mM Y-27632を加えた。
(3-2)プレートのコーティング
6ウェルマイクロプレートにPBS(-)を1.5ml/wellを入れ、Plus#1ラミニンE8(コート量:0.5μg/cm2)を4.8μg/well加え、37℃ CO2 5%インキュベーターで60分反応させた後、維持培養培地1ml/well加え培地をなじませた後、上澄みを除去した。同様に、Plus#2および#3ラミニンE8をコーティングしたウェルマイクロプレートを準備した(いずれもコート量は0.5μg/cm2)。それぞれのコーティングプレートは、維持培養培地(Y-27632入り)を1.5ml/well加え、インキュベーター下で保管した。なお、マトリゲル溶液については上記条件下で、0.1~30μg/cm2の範囲になるようにプレートへ添加した。
培地を除去し、PBS4mlで一回洗浄した後に、PBSを完全に吸引除去し、CTK液を0.5ml加え、37℃でインキュベートした。殆どのフィーダー細胞が剥がれたらCTK液を吸引し、4mlのPBSで1回洗浄、その後にX0.5 TrypLE Select(Invitrogen社より購入)を600μl/wellずつ加えてなじませ、37℃ CO2 5%インキュベーターで1分さらに3分反応させた。その後、インキュベーターから取り出し顕微鏡で細胞の様子を観察し、細胞間接着が破壊され細胞が丸くなっている様子を確認した。先に加えたX0.5 TrypLE Selectを除去し、持培養用培地を3ml/well加えた後にセルスクレーパーで細胞を剥がした。
(3-4)細胞の培養
フィーダー細胞を除去し、単一に分散した32R1細胞13,000個を上記にて予め調製したコーティングプレート(6-well plate)に播種し、37℃ CO2 5%インキュベーターで単一分散培養を行った。翌日、維持培養用培地に交換した。培地交換は1日おきに行い、培養開始後6、7日頃から毎日行った。細胞の継代は7~9日ごとに行った。培養開始7日目の継代前の細胞の状態を写真撮影した(対物4倍)。その後10代継代培養を行った後、Oct3/4、SSEA-4およびTRA-1-60について免疫染色を行い、位相差像および蛍光像を写真撮影した(それぞれ対物10倍)。
培養開始7日目における継代前のヒトiPS細胞の状態を図6に示した。図6中、上段左からマトリゲルコート(図中、Matrigel(コート量:30μg/cm2))、rhLM511E8コート(図中、E8)、Plus#1ラミニンE8コート(図中、E8plus#1)、下段左からPlus#2ラミニンE8コート(図中、E8plus#2)、Plus#3ラミニンE8コート(図中、E8plus#3)である。各種細胞外基質をコーティングした培養器において、32R1細胞の生着が確認された。
(1)ヒトiPS細胞
実施例3、6と同じ32R1細胞を使用した。
(2)細胞外基質
実施例5と同様に、Plus#1ラミニンE8、Plus#2ラミニンE8、全長ラミニン511およびマトリゲルを使用した。
実施例3と同様にプレートのコーティングを行った。実施例6と同様にフィーダー細胞を除去し、単一に分散した32R1細胞13,000個を、予め調製したコーティングプレート(6-well plate)に播種し、37℃ CO2 5%インキュベーターで単一分散培養を行った。翌日、維持培養用培地に交換した。培地交換は1日おきに行い、培養開始後6、7日頃から毎日行った。
各種細胞外基質をコーティングした培養器で32R1細胞の単一分散培養を行い、7日間培養を行った後、増殖した細胞コロニーをアルカリフォスファターゼ(ALP)染色した結果を図8に示した。図8中、上段左からコートなし(図中、None)、マトリゲルコート(図中、Matrigel)、全長ラミニン511コート(図中、LN511FL)、下段左からPlus#1ラミニンE8コート(図中、LN511E8plus#1)、Plus#2ラミニンE8コート(図中、LN511E8plus#2)である。アルカリフォスファターゼ染色により、下段のPlus#1ラミニンE8コートおよびPlus#2ラミニンE8コートの培養器において32R1細胞の良好な増殖が観察された。一方、上段のコートなしおよびマトリゲルコートの培養器では32R1細胞はほとんど観察されなかった。以上の結果から、Plus#1ラミニンE8またはPlus#2ラミニンE8をコーティングした培養基材を用いれば、単一分散によるヒトiPS細胞の培養方法を容易に提供できることが示された。
(1)実験方法
上記実施例6および7のように予め樹立されたヒトiPS細胞株を用いるのではなく、Plus#1ラミニンE8またはPlus#2ラミニンE8をコーティングした培養器を用いてヒトiPS細胞の樹立を試みた。コーティング濃度は0.5μg/cm2とした。具体的には、Plus#1ラミニンE8またはPlus#2ラミニンE8をコーティングしたディッシュ上で、米国仮出願61/521,153に記載の方法に従い、成人皮膚由来線維芽細胞(HDF1388細胞)にエピソーマルプラスミドベクターpCEB-hSK-OおよびpCEB-hUL-Gを用いて初期化遺伝子を導入し、維持培養培地(mTeSR1(StemCell Technologies社)とNutriStem(コスモバイオ社)の1:1混合溶液)で培養を行った。初期化遺伝子の導入後30日目にヒトiPS細胞のコロニー数をカウントした。
これらのエピソーマルプラスミドは、Okita et al., “A more efficient method to generate integration-free human iPS cells”, Nature Methods, 8(5), 409 (2011)および国際公報WO2011/016588に記載のプラスミド等を用いて作製した。
3つの独立した実験(Exp.1、2、および3)における、ノンコートディッシュ、Plus#1ラミニンE8コートディッシュおよびPlus#2ラミニンE8コートディッシュ条件下でのヒトiPS細胞コロニー数(樹立数)を図9に示した。いずれの実験においても左がノンコートディッシュ、中央がPlus#1ラミニンE8コートディッシュ、右がPlus#2ラミニンE8コートディッシュを表す。図9から明らかなように、Exp.2のPlus#1ラミニンE8コートディッシュを除き、Plus#1ラミニンE8コートディッシュまたはPlus#2ラミニンE8コートディッシュにおけるヒトiPS細胞コロニー数(樹立数)が、ノンコートディッシュより増加した。この結果から、Plus#1ラミニンE8またはPlus#2ラミニンE8をコーティングした培養基材は、iPS細胞の樹立においても非常に有用であることが示された。
Claims (18)
- ラミニン、または、ヘテロ3量体を形成しているラミニンフラグメントのα鎖のN末端、α鎖のC末端、β鎖のN末端およびγ鎖のN末端の少なくとも1箇所に細胞増殖制御分子が結合していることを特徴とする改変ラミニン。
- 細胞増殖制御分子が、細胞接着分子である請求項1に記載の改変ラミニン。
- 細胞増殖制御分子が、増殖因子結合分子である請求項1に記載の改変ラミニン。
- ラミニンフラグメントが、インテグリン結合活性を有していることを特徴とする請求項1~3のいずれかに記載の改変ラミニン。
- ラミニンフラグメントが、ラミニンE8フラグメントである請求項4に記載の改変ラミニン。
- ラミニンが、α1~α5から選択される1種のα鎖、β1~β3から選択される1種のβ鎖、γ1~γ3から選択される1種のγ鎖からなることを特徴とする請求項1~5のいずれかに記載の改変ラミニン。
- ラミニンが、ラミニンα5β1γ1またはラミニンα3β3γ2である請求項6に記載の改変ラミニン。
- 細胞接着分子が、以下の(a)~(e)から選択される少なくとも1種以上であることを特徴とする請求項2に記載の改変ヒトラミニン。
(a)インテグリンと結合する細胞接着分子
(b)膜結合型プロテオグリカンと結合する細胞接着分子
(c)ジスコイジンドメイン受容体と結合する細胞接着分子
(d)ジストログリカンと結合する細胞接着分子
(e)細胞表面の糖鎖と結合する細胞接着分子 - 細胞接着分子が、以下の(a)~(k)から選択される少なくとも1種以上であることを特徴とする請求項2に記載の改変ヒトラミニン。
(a)フィブロネクチンまたはその細胞接着活性部位を含むフラグメント
(b)コラーゲンまたはその細胞接着活性部位を含むフラグメント
(c)ビトロネクチンまたはその細胞接着活性部位を含むフラグメント
(d)ネフロネクチンまたはその細胞接着活性部位を含むフラグメント
(e)オステオポンティンまたはその細胞接着活性部位を含むフラグメント
(f)MAEGまたはその細胞接着活性部位を含むフラグメント
(g)テネイシンまたはその細胞接着活性部位を含むフラグメント
(h)SVEP1またはその細胞接着活性部位を含むフラグメント
(i)TGF-β1 latency associated peptideまたはその細胞接着活性部位を含むフラグメント
(j)TGF-β3 latency associated peptideまたはその細胞接着活性部位を含むフラグメント
(k)ラミニンα鎖の球状ドメイン4および/または5 - 増殖因子結合分子が、以下の(a)~(f)から選択される少なくとも1種以上であることを特徴とする請求項3に記載の改変ヒトラミニン。
(a)パールカンまたはその増殖因子結合部位を含むフラグメント
(b)アグリンまたはその増殖因子結合部位を含むフラグメント
(c)XVIII型コラーゲンまたはその増殖因子結合部位を含むフラグメント
(d)シンデカンまたはその増殖因子結合部位を含むフラグメント
(e)グリピカンまたはその増殖因子結合部位を含むフラグメント
(f)latent TGF-β binding proteinまたはその増殖因子結合部位を含むフラグメント - ヒト由来である請求項1~10のいずれかに記載の改変ラミニン。
- 哺乳動物細胞の培養方法であって、請求項1~11のいずれかに記載の改変ヒトラミニンの存在下で培養することを特徴とする培養方法。
- 哺乳動物細胞が、ES細胞、iPS細胞または体性幹細胞である請求項12に記載の培養方法。
- フィーダー細胞を用いないことを特徴とする請求項12または13に記載の培養方法。
- 請求項1~11のいずれかに記載の改変ヒトラミニンがコーティングされていることを特徴とする培養基材。
- 改変ヒトラミニンが0.03~25μg/cm2の濃度でコーティングされていることを特徴とする請求項15に記載の培養基材。
- 請求項1~11のいずれかに記載の改変ラミニンの存在下で、核初期化物質を体細胞に接触させる工程を含むことを特徴とするiPS細胞の樹立方法。
- 前記核初期化物質は、Octファミリー、Soxファミリー、Klfファミリー、LinファミリーおよびGlisファミリー並びにそれらをコードする核酸からなる群より選択される1種類以上の物質を含むことを特徴とする請求項17に記載のiPS細胞の樹立方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/110,063 US9758765B2 (en) | 2011-04-08 | 2012-04-09 | Modified laminin and use thereof |
EP12767444.8A EP2695894B1 (en) | 2011-04-08 | 2012-04-09 | Modified laminin and use thereof |
CN201280017315.6A CN103649112B (zh) | 2011-04-08 | 2012-04-09 | 改造层粘连蛋白及其利用 |
JP2013508961A JP5761826B2 (ja) | 2011-04-08 | 2012-04-09 | 改変ラミニンおよびその利用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-086590 | 2011-04-08 | ||
JP2011086590 | 2011-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012137970A1 true WO2012137970A1 (ja) | 2012-10-11 |
Family
ID=46969358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/059720 WO2012137970A1 (ja) | 2011-04-08 | 2012-04-09 | 改変ラミニンおよびその利用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9758765B2 (ja) |
EP (1) | EP2695894B1 (ja) |
JP (2) | JP5761826B2 (ja) |
CN (1) | CN103649112B (ja) |
WO (1) | WO2012137970A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014103534A1 (ja) | 2012-12-28 | 2014-07-03 | 国立大学法人大阪大学 | コラーゲン結合性分子を付加した改変ラミニンおよびその利用 |
WO2014168157A1 (ja) * | 2013-04-08 | 2014-10-16 | 独立行政法人医薬基盤研究所 | 肝幹前駆様細胞の培養方法及びその培養物 |
WO2014199754A1 (ja) | 2013-06-12 | 2014-12-18 | 国立大学法人大阪大学 | ラミニンフラグメントが乾燥状態でコーティングされている細胞培養器具 |
JP2017085963A (ja) * | 2015-11-10 | 2017-05-25 | 国立大学法人京都大学 | ラミニンフラグメント含有培地を用いる細胞培養方法 |
JP2018019654A (ja) * | 2016-08-04 | 2018-02-08 | 日立化成株式会社 | 培養用生成物、及び培養容器 |
WO2018088501A1 (ja) | 2016-11-11 | 2018-05-17 | 国立大学法人大阪大学 | 多能性幹細胞から体細胞への分化誘導方法 |
US10428311B2 (en) | 2014-07-16 | 2019-10-01 | Osaka University | Method for enhancing activity of laminin fragments as cell culture matrix |
US10696948B2 (en) | 2014-09-16 | 2020-06-30 | Osaka University | Method for preparing pluripotent stem cell-derived cardiomyocyte population |
WO2021025027A1 (ja) | 2019-08-06 | 2021-02-11 | 花王株式会社 | 皮膚由来多能性前駆細胞の作製方法 |
WO2021200744A1 (ja) | 2020-03-31 | 2021-10-07 | Cell Exosome Therapeutics株式会社 | 増殖細胞の生産方法、細胞生産物の生産方法、間葉系幹細胞集団およびその生産方法、幹細胞の培養上清およびその生産方法、並びに治療剤 |
WO2021225171A1 (ja) | 2020-05-08 | 2021-11-11 | 国立大学法人大阪大学 | フィブリノゲンフラグメントとラミニンフラグメントを含むキメラタンパク質およびその利用 |
WO2022244670A1 (ja) * | 2021-05-18 | 2022-11-24 | 国立大学法人京都大学 | 多能性幹細胞の製造方法 |
WO2024019080A1 (ja) * | 2022-07-19 | 2024-01-25 | 国立大学法人 長崎大学 | 血管内皮増殖因子を高発現する臍帯由来間葉系細胞の製造方法、および肺疾患治療用医薬組成物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3375860A4 (en) | 2015-11-10 | 2019-07-03 | Nikkiso Co., Ltd. | CELL SUPPORT COMPOSITE AND PROCESS FOR PRODUCING CELL SUPPORT COMPOSITE |
JP6957893B2 (ja) | 2017-02-20 | 2021-11-02 | 東洋製罐グループホールディングス株式会社 | 細胞培養方法、及び細胞培養システム |
CN108715833B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种负载血小板裂解液的微球制备方法 |
CN108794639B (zh) * | 2018-07-03 | 2020-11-20 | 广州澳特朗生物技术有限公司 | 一种重组纤连蛋白及其应用 |
CN110845603B (zh) * | 2019-10-31 | 2021-07-02 | 山西锦波生物医药股份有限公司 | 人胶原蛋白17型多肽、其生产方法和用途 |
CN111500629B (zh) * | 2020-04-17 | 2021-11-19 | 安徽中盛溯源生物科技有限公司 | 一种高表达层粘连蛋白-511变体的方法及其应用 |
CN111454350B (zh) * | 2020-06-01 | 2020-12-29 | 广东丸美生物技术股份有限公司 | 一种重组纤连蛋白突变体及其应用 |
JP2022103121A (ja) | 2020-12-25 | 2022-07-07 | 国立大学法人信州大学 | 細胞培養部材及びその表面改質方法 |
CN114702571B (zh) * | 2022-04-24 | 2023-07-25 | 安博威生物科技(厦门)有限公司 | 一种具有促进干细胞定植的纤连蛋白及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008084401A2 (en) * | 2007-01-04 | 2008-07-17 | Karl Tryggvason | Composition and method for enabling proliferation of pluripotent stem cells |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2010098419A1 (en) | 2009-02-27 | 2010-09-02 | Kyoto University | Novel nuclear reprogramming substance |
WO2011016588A1 (en) | 2009-08-07 | 2011-02-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2011043405A1 (ja) * | 2009-10-08 | 2011-04-14 | 国立大学法人大阪大学 | ヒト多能性幹細胞用培養基材およびその利用 |
WO2011102531A1 (en) | 2010-02-16 | 2011-08-25 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2712304C (en) * | 1994-06-10 | 2011-10-25 | United States Surgical Corporation | Recombinant chimeric proteins and methods of use thereof |
WO2007023875A1 (ja) | 2005-08-23 | 2007-03-01 | Oriental Yeast Co., Ltd. | ラミニン5を利用した間葉系幹細胞の培養技術 |
CN102131919B (zh) | 2008-03-31 | 2017-05-03 | 东方酵母工业株式会社 | 一种增殖多能性干细胞的方法 |
-
2012
- 2012-04-09 JP JP2013508961A patent/JP5761826B2/ja active Active
- 2012-04-09 US US14/110,063 patent/US9758765B2/en active Active
- 2012-04-09 EP EP12767444.8A patent/EP2695894B1/en active Active
- 2012-04-09 CN CN201280017315.6A patent/CN103649112B/zh active Active
- 2012-04-09 WO PCT/JP2012/059720 patent/WO2012137970A1/ja active Application Filing
-
2015
- 2015-06-05 JP JP2015114471A patent/JP2015178526A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008084401A2 (en) * | 2007-01-04 | 2008-07-17 | Karl Tryggvason | Composition and method for enabling proliferation of pluripotent stem cells |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2010098419A1 (en) | 2009-02-27 | 2010-09-02 | Kyoto University | Novel nuclear reprogramming substance |
WO2011016588A1 (en) | 2009-08-07 | 2011-02-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2011043405A1 (ja) * | 2009-10-08 | 2011-04-14 | 国立大学法人大阪大学 | ヒト多能性幹細胞用培養基材およびその利用 |
WO2011102531A1 (en) | 2010-02-16 | 2011-08-25 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
Non-Patent Citations (54)
Title |
---|
"Integrin-binding Sites within the Globular Domain of Human Laminin-10", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 10946 - 10954 |
CELL RESEARCH, 2008, pages 600 - 603 |
CELL STEM CELL, vol. 2, 2008, pages 525 - 528 |
CELL, vol. 126, 2006, pages 663 - 676 |
CELL, vol. 131, 2007, pages 861 - 872 |
CELL, vol. 136, 2009, pages 411 - 419 |
EDGAR D.; TIMPL R.; THOENEN H.: "The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival", EMBO J., vol. 3, 1984, pages 1463 - 1468, XP055222218 |
FUSAO KIMIZUKA; YOICHI OHDATE; YASUTOSHI KAWASE; TOMOKO SHIMOJYO; YUKI TAGUCHI; KIMIKAZU HASHINO; SHOICHI GOTO; HIDETAKA HASHI; IK: "Role of type III homology repeats in cell adhesive function within the cell-binding domain of fibronectin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, 1999, pages 3045 - 3051 |
GOODMAN SL.; DEUTZMANN R.; VON DER MARK K.: "Two distinct cell-binding domains in laminin can independently promote nonneuronal cell adhesion and spreading", J. CELL BIOL., vol. 105, 1987, pages 589 - 598, XP055304702, DOI: doi:10.1083/jcb.105.1.589 |
HIROKI AKAMATSU; KEIKO ICHIHARA-TANAKA; KEIICHI OZONO; WATARU KAMIIKE; HIKARU MATSUDA; KIYOTOSHI SEKIGUCHI: "Suppression of Transformed Phenotypes of Human Fibrosarcoma Cells by Overexpression of Recombinant Fibronectin", CANCER RESEARCH, vol. 56, 1996, pages 4541 - 4546 |
HIROYUKI IDO; AYA NAKAMURA; REIKO KOBAYASHI; SHUNSUKE ITO; SHAOLIANG LI; SUGIKO FUTAKI; KIYOTOSHI SEKIGUCHI: "The requirement of the glutamic acid residue at the third position from the carboxyl termini of the laminin y chains in integrin binding by laminins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, 2007, pages 11144 - 11154, XP008153460, DOI: doi:10.1074/jbc.M609402200 |
HIROYUKI IDO; KENJI HARADA; SUGIKO FUTAKI; YOSHITAKA HAYASHI; RYOKO NISHIUCHI; YUKO NATSUKA; SHAOLIANG LI; YOSHINAO WADA; ARIANA C: "Molecular dissection of the a-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 10946 - 10954 |
HIROYUKI IDO; KENJI HARADA; YOSHIKO YAGI; KIYOTOSHI SEKIGUCHI: "Probing the integrin-binding site within the globular domain of laminin-511 with the function-blocking monoclonal antibody 4C7", MATRIX BIOLOGY, vol. 25, no. 2, 2006, pages 112 - 117 |
JUNICHI TAKAGI; HAROLD P. ERICKSON; TIMOTHY A. SPRINGER: "C-terminal opening mimics inside-out activation of integrin ?5?1", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 8, no. 5, 2001, pages 412 - 416 |
KANO, F. ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 322, 2006, pages 357 - 365 |
KAZUTOSHI TAKAHASHI; KOJI TANABE; MARI OHNUKI; MEGUMI NARITA; TOMOKO ICHISAKA; KIICHIRO TOMODA; SHINYA YAMANAKA: "Induction of pluripotent stem cells from adult human fibroblasts by defined factors", CELL, vol. 131, no. 5, 2007, pages 861 - 872, XP008155962, DOI: doi:10.1016/j.cell.2007.11.019 |
KIYOTOSHI SEKIGUCHI; SEN-ITIROH HAKOMORI: "Domain structure of human plasma fibronectin. Differences and similarities between human and hamster fibronectins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 258, 1983, pages 3967 - 3973 |
KONDO, E. ET AL., MOL. CANCER THER., vol. 3, no. 12, 2004, pages 1623 - 1630 |
LI, Y. ET AL., BIOTECHNOL. BIOENG., vol. 91, 2005, pages 688 - 698 |
LIU, Y. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 346, 2006, pages 131 - 139 |
LU, J. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 103, 2006, pages 5688 - 5693 |
MAEKAWA, M. ET AL., NATURE, vol. 474, 2011, pages 225 - 229 |
MAHERALI, N. ET AL., CELL STEM CELL, vol. 1, 2007, pages 55 - 70 |
MASATO NAKAGAWA; NANAKO TAKIZAWA; MEGUMI NARITA; TOMOKO ICHISAKA; SHINYA YAMANAKA: "Promotion of direct reprogramming by transformation-deficient Myc", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 32, 2010, pages 14152 - 14157, XP008151220, DOI: doi:10.1073/pnas.1009374107 |
MCMAHON, A. P.; BRADLEY, A., CELL, vol. 62, 1990, pages 1073 - 1085 |
MIYAZAKI T; FUTAKI S; HASEGAWA K; KAWASAKI M; SANZEN N; HAYASHI M, KAWASE E; SEKIGUCHI K; NAKATSUJI N; SUEMORI H.: "Recombinant human laminin isoforms can support the undifferentiated growth of human embryonic stem cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 375, 2008, pages 27 - 35 |
MIYAZAKI,T. ET AL.: "Recombinant human laminin isoforms can support the undifferentiated growth of human embryonic stem cells", BIOCHEM. BIOPHYS.RES.COMMUN., vol. 375, no. 1, 2008, pages 27 - 32, XP024520467 * |
NAKAGAWA, M. ET AL., NAT. BIOTETHNOL., vol. 26, 2008, pages 101 - 106 |
NAT. CELL BIOL., vol. 11, 2009, pages 197 - 203 |
NATURE BIOTECHNOLOGY, vol. 26, 2008, pages 101 - 106 |
NATURE, vol. 08436, 2009 |
NATURE, vol. 451, 2008, pages 141 - 146 |
NATURE, vol. 454, 2008, pages 646 - 650 |
NATURE, vol. 474, 2011, pages 225 - 229 |
OKITA ET AL.: "A more efficient method to generate integration-free human iPS cells", NATURE METHODS, vol. 8, no. 5, 2011, pages 409, XP055176852, DOI: doi:10.1038/nmeth.1591 |
OKITA, K. ET AL., NATURE, vol. 448, 2007, pages 313 - 317 |
PROC. NATL. ACAD. SCI. USA., vol. 107, 2010, pages 14152 - 14157 |
RI-ICHIROH MANABE; NAOKO OH-E; TOSHINAGA MAEDA; TOMOHIKO FUKUDA; KIYOTOSHI SEKIGUCHI: "Modulation of cell adhesive activity of fibronectin by the alternatively spliced EDA segment", THE JOURNAL OF CELL BIOLOGY, vol. 139, 1997, pages 295 - 307, XP002193809, DOI: doi:10.1083/jcb.139.1.295 |
RODIN,S. ET AL.: "Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511", NAT.BIOTECHNOL., vol. 28, no. 6, 2010, pages 611 - 615, XP009135150 * |
SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
SCIENCE, vol. 324, 2009, pages 797 - 801 |
See also references of EP2695894A4 |
SHAOLIANG LI; CHISEI SHIMONO; NAOKO NORIOKA; ITSUKO NAKANO; TETSUO OKUBO; YOSHIKO YAGI; MARIA HAYASHI; YUYA SATO; HITOMI FUJISAKI;: "Activin A Binds to Perlecan through Its Pro-region That Has Heparin/Heparan Sulfate Binding Activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 47, 2010, pages 36645 - 36655, XP055266811, DOI: doi:10.1074/jbc.M110.177865 |
SHOICHI SASAKI ET AL.: "Shinkei Soshiki Kochiku no Tameno Kinosei Matrix Tanpakushitsu no Sekkei", 90TH ANNUAL MEETING OF THE CHEMICAL SOCIETY OF JAPAN IN SPRING KOEN YOKOSHU, 2010, pages 605, XP008169686 * |
STEM CELLS, vol. 26, 2008, pages 1998 - 2005 |
TAKAHASHI, K. ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
TAKAHASHI, K.; YAMANAKA, S., CELL, vol. 126, 2006, pages 663 - 676 |
UWE WINZEN; GREGORY J. COLE; WILLI HALFTER: "Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, 2008, pages 30106 - 30114, XP055336415, DOI: doi:10.1074/jbc.M212676200 |
VALLIER, L. ET AL., J. CELL SCI., vol. 118, 2005, pages 4495 - 4509 |
WELSH,E.R. ET AL.: "Engineering the extracellular matrix: a novel approach to polymeric biomaterials. I. Control of the physical properties of artificial protein matrices designed to support adhesion of vascular endothelial cells", BIOMACROMOLECULES., vol. 1, no. 1, 2000, pages 23 - 30, XP002988982 * |
WERNIG, M. ET AL., NATURE, vol. 448, 2007, pages 318 - 324 |
YAO, S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 103, 2006, pages 6907 - 6912 |
YU, J. ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
YUYA SATO; TOSHIHIKO UEMURA; KEISUKE MORIMITSU; RYOKO SATO-NISHIUCHI; RI-ICHIROH MANABE; JUNICHI TAKAGI; MASASHI YAMADA; KIYOTOSHI: "Molecular basis of the recognition of nephronectin by integrin ?8?1", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, 2009, pages 14524 - 14536, XP055063092, DOI: doi:10.1074/jbc.M900200200 |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104884468B (zh) * | 2012-12-28 | 2018-08-31 | 国立大学法人大阪大学 | 附加有胶原结合性分子的改造层粘连蛋白及其利用 |
CN104884468A (zh) * | 2012-12-28 | 2015-09-02 | 国立大学法人大阪大学 | 附加有胶原结合性分子的改造层粘连蛋白及其利用 |
JP5858411B2 (ja) * | 2012-12-28 | 2016-02-10 | 国立大学法人大阪大学 | コラーゲン結合性分子を付加した改変ラミニンおよびその利用 |
JPWO2014103534A1 (ja) * | 2012-12-28 | 2017-01-12 | 国立大学法人大阪大学 | コラーゲン結合性分子を付加した改変ラミニンおよびその利用 |
WO2014103534A1 (ja) | 2012-12-28 | 2014-07-03 | 国立大学法人大阪大学 | コラーゲン結合性分子を付加した改変ラミニンおよびその利用 |
US10000554B2 (en) | 2012-12-28 | 2018-06-19 | Osaka University | Modified laminin containing collagen binding molecule and use thereof |
WO2014168157A1 (ja) * | 2013-04-08 | 2014-10-16 | 独立行政法人医薬基盤研究所 | 肝幹前駆様細胞の培養方法及びその培養物 |
WO2014199754A1 (ja) | 2013-06-12 | 2014-12-18 | 国立大学法人大阪大学 | ラミニンフラグメントが乾燥状態でコーティングされている細胞培養器具 |
US10428311B2 (en) | 2014-07-16 | 2019-10-01 | Osaka University | Method for enhancing activity of laminin fragments as cell culture matrix |
US10696948B2 (en) | 2014-09-16 | 2020-06-30 | Osaka University | Method for preparing pluripotent stem cell-derived cardiomyocyte population |
JP2017085963A (ja) * | 2015-11-10 | 2017-05-25 | 国立大学法人京都大学 | ラミニンフラグメント含有培地を用いる細胞培養方法 |
JP2018019654A (ja) * | 2016-08-04 | 2018-02-08 | 日立化成株式会社 | 培養用生成物、及び培養容器 |
JP7038361B2 (ja) | 2016-11-11 | 2022-03-18 | 国立大学法人大阪大学 | 多能性幹細胞から体細胞への分化誘導方法 |
WO2018088501A1 (ja) | 2016-11-11 | 2018-05-17 | 国立大学法人大阪大学 | 多能性幹細胞から体細胞への分化誘導方法 |
JPWO2018088501A1 (ja) * | 2016-11-11 | 2019-10-03 | 国立大学法人大阪大学 | 多能性幹細胞から体細胞への分化誘導方法 |
CN109937251A (zh) * | 2016-11-11 | 2019-06-25 | 国立大学法人大阪大学 | 由多能干细胞向体细胞的分化诱导方法 |
US11959103B2 (en) | 2016-11-11 | 2024-04-16 | Osaka University | Method for inducing pluripotent stem cells to differentiate into somatic cells |
CN109937251B (zh) * | 2016-11-11 | 2023-12-29 | 国立大学法人大阪大学 | 由多能干细胞向体细胞的分化诱导方法 |
WO2021025027A1 (ja) | 2019-08-06 | 2021-02-11 | 花王株式会社 | 皮膚由来多能性前駆細胞の作製方法 |
JP7285520B2 (ja) | 2019-08-06 | 2023-06-02 | 花王株式会社 | 皮膚由来多能性前駆細胞の作製方法 |
JP2021023293A (ja) * | 2019-08-06 | 2021-02-22 | 花王株式会社 | 皮膚由来多能性前駆細胞の作製方法 |
EP4155389A2 (en) | 2020-03-31 | 2023-03-29 | Cell Exosome Therapeutics Inc. | Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent |
WO2021200744A1 (ja) | 2020-03-31 | 2021-10-07 | Cell Exosome Therapeutics株式会社 | 増殖細胞の生産方法、細胞生産物の生産方法、間葉系幹細胞集団およびその生産方法、幹細胞の培養上清およびその生産方法、並びに治療剤 |
WO2021225171A1 (ja) | 2020-05-08 | 2021-11-11 | 国立大学法人大阪大学 | フィブリノゲンフラグメントとラミニンフラグメントを含むキメラタンパク質およびその利用 |
EP4148133A4 (en) * | 2020-05-08 | 2023-11-22 | Osaka University | CHIMERIC PROTEIN CONTAINING FIBRINOGEN FRAGMENT AND LAMIN INFRAGMENT AND USE THEREOF |
WO2022244670A1 (ja) * | 2021-05-18 | 2022-11-24 | 国立大学法人京都大学 | 多能性幹細胞の製造方法 |
WO2024019080A1 (ja) * | 2022-07-19 | 2024-01-25 | 国立大学法人 長崎大学 | 血管内皮増殖因子を高発現する臍帯由来間葉系細胞の製造方法、および肺疾患治療用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20140127806A1 (en) | 2014-05-08 |
JP5761826B2 (ja) | 2015-08-12 |
CN103649112B (zh) | 2017-07-18 |
JPWO2012137970A1 (ja) | 2014-07-28 |
CN103649112A (zh) | 2014-03-19 |
JP2015178526A (ja) | 2015-10-08 |
EP2695894A4 (en) | 2014-10-08 |
EP2695894B1 (en) | 2017-11-01 |
US9758765B2 (en) | 2017-09-12 |
EP2695894A1 (en) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5761826B2 (ja) | 改変ラミニンおよびその利用 | |
DK2821480T3 (en) | Culture substrate for human pluripotent stem cells and their use | |
JP5858411B2 (ja) | コラーゲン結合性分子を付加した改変ラミニンおよびその利用 | |
US10287541B2 (en) | Cell culture vessel coated with laminin fragment in dry state | |
EP3170892B1 (en) | Method for enhancing activity of laminin fragments as cell culture matrix | |
CA3004251C (en) | Cell culture method using laminin fragment-containing medium | |
JP6388872B2 (ja) | ポリペプチド組成物およびこれを用いた多能性幹細胞の培養方法 | |
JP6169710B2 (ja) | 多能性幹細胞の培養方法、培養用キット及び多能性幹細胞培養用培地 | |
JPWO2017026156A1 (ja) | 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12767444 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013508961 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2012767444 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012767444 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14110063 Country of ref document: US |